{
  "meta": {
    "title": "24_Inicet_May_2024_Mock_Test-1_Part-2_-_19-04-2024",
    "url": "https://brainandscalpel.vercel.app/24-inicet-may-2024-mock-test-1-part-2-19-04-2024-63e99d6d.html",
    "scrapedAt": "2025-11-29T17:23:29.973Z"
  },
  "questions": [
    {
      "id": 41018,
      "choices": [
        {
          "id": 163776,
          "text": "<p>​​​​<span style=\"font-size:14.0pt;\">Frost bite</span></p>"
        },
        {
          "id": 163777,
          "text": "<p>​​​​​<span style=\"font-size:14.0pt;\">Acute interstitial pneumonia</span></p>"
        },
        {
          "id": 163778,
          "text": "<p>​​​​​<span style=\"font-size:14.0pt;\">Non-cardiogenic pulmonary oedema</span></p>"
        },
        {
          "id": 163779,
          "text": "<p><span style=\"font-size:14.0pt;\">Pneumonia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:14.0pt;\">A 24-year-old medical student develops extreme shortness of breath and develops blue fingertips and bilateral crackles after trekking in Ladakh. What is the probable diagnosis?</span></p>",
      "unique_key": "Q6292963",
      "question_audio": null,
      "question_video": null,
      "map_id": 4584550,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:14.0pt;\"><strong>Ans. C) Non cardiogenic pulmonary oedema</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:14.0pt;\">The symptoms suggest High Altitude Pulmonary Edema (HAPE), which is a form of non-cardiogenic pulmonary edema and a serious, potentially fatal condition.</span></li><li><span style=\"font-size:14.0pt;\">HAPE occurs when individuals ascend to high altitudes without proper acclimatization.</span></li><li><span style=\"font-size:14.0pt;\">It is characterized by extreme shortness of breath, cyanosis (blue fingertips), and bilateral crackles due to the accumulation of fluid in the lungs.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option A.</strong> <strong>Frostbite</strong>: This typically affects the extremities and leads to the freezing of skin and underlying tissues, which doesn't directly cause shortness of breath or bilateral lung crackles.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option B.</strong> <strong>Acute interstitial pneumonia</strong>: Also known as Hamman-Rich syndrome, this condition causes rapid lung function deterioration and can have similar respiratory symptoms, but it is not related to high-altitude exposure.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option D.</strong> <strong>Pneumonia</strong>: While pneumonia can cause shortness of breath and crackles, the setting of recent high-altitude exposure makes non-cardiogenic pulmonary edema a more likely diagnosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:14.0pt;\">In a young individual with acute respiratory distress and bilateral crackles following rapid ascent to high altitude, consider High Altitude Pulmonary Edema (HAPE), which is non-cardiogenic in nature.</span></li><li><span style=\"font-size:14.0pt;\">It is important to distinguish HAPE from other forms of pulmonary edema and respiratory conditions like pneumonia, which have different treatments and implications.</span></li></ul>",
      "correct_choice_id": 163778,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41020,
      "choices": [
        {
          "id": 163784,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">McArdle&rsquo;s&nbsp;disease </span></span></span></span></p>"
        },
        {
          "id": 163785,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cori&rsquo;s disease </span></span></span></span></p>"
        },
        {
          "id": 163786,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Von Gierke&rsquo;s disease </span></span></span></span></p>"
        },
        {
          "id": 163787,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pompe&rsquo;s disease</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child came with exercise intolerance. On investigation, blood pH is 7.3, Fasting Blood Sugar is 60 mg%, hypertriglyceridemia, ketosis and lactic acidosis are present. The child had hepatomegaly and renomegaly. Biopsy of liver and kidney showed increased glycogen content. What is the diagnosis?</span></span></span></span></p>",
      "unique_key": "Q6846489",
      "question_audio": null,
      "question_video": null,
      "map_id": 4584672,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C)</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Von Gierke&rsquo;s disease</strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Von Gierke&#39;s disease, also known as <strong>Glycogen Storage Disease Type I (GSD I)</strong>, is caused by a deficiency in the enzyme glucose-6-phosphatase. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This enzyme is crucial for the final steps of glycogenolysis and gluconeogenesis, which convert glycogen and other substrates into glucose. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Its deficiency leads to an inability to maintain normal blood glucose levels during fasting, resulting in hypoglycemia. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The accumulated substrates also lead to increased production of lactic acid (lactic acidosis) and triglycerides (hypertriglyceridemia). </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The disease commonly presents with hepatomegaly and renomegaly due to the accumulation of glycogen and fat in these organs.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>McArdle&rsquo;s disease (GSD V)</strong>: This condition is characterized by a deficiency in muscle glycogen phosphorylase, leading to exercise intolerance, muscle cramps, and myoglobinuria (muscle breakdown leading to red-colored urine), especially after exercise, but does not typically feature hepatomegaly, renomegaly, or the metabolic abnormalities described.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Cori&rsquo;s disease (GSD III)</strong>: Cori&#39;s disease involves a deficiency in the debranching enzyme (amylo-1,6-glucosidase), leading to abnormal glycogen structure and accumulation in the liver and muscles. While it can present with hepatomegaly and hypoglycemia, the clinical presentation is typically less severe than in Von Gierke&#39;s disease, and it does not typically cause renomegaly.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Pompe&rsquo;s disease (GSD II)</strong>: This condition is due to a deficiency in the lysosomal enzyme acid alpha-glucosidase, leading to glycogen accumulation in lysosomes, particularly affecting muscle tissue, including the heart. It presents predominantly with cardiomyopathy and muscle weakness rather than the symptoms and metabolic disturbances associated with Von Gierke&rsquo;s disease.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Von Gierke&#39;s disease (GSD Type I) presents with hypoglycemia, lactic acidosis, hypertriglyceridemia, hepatomegaly, and renomegaly due to a deficiency in glucose-6-phosphatase, leading to impaired glycogenolysis and gluconeogenesis. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This results in the accumulation of glycogen and fat in the liver and kidneys, and metabolic abnormalities.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163786,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41022,
      "choices": [
        {
          "id": 163792,
          "text": "<p><span style=\"font-size:14.0pt;\">Histamine, which stimulates gastric acid production, potentially exacerbating ulcer symptoms.</span></p>"
        },
        {
          "id": 163793,
          "text": "<p><span style=\"font-size:14.0pt;\">Gastrin, which promotes mucus production and provides protection against ulcers.</span></p>"
        },
        {
          "id": 163794,
          "text": "<p><span style=\"font-size:14.0pt;\">Pepsinogen, an enzyme involved in protein digestion within the stomach.</span></p>"
        },
        {
          "id": 163795,
          "text": "<p><span style=\"font-size:14.0pt;\">Secretin, a hormone that regulates pancreatic enzyme secretion, influencing digestion.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:14.0pt;\">In a patient with chronic gastritis and peptic ulcer disease, it is important to understand the role of specific stomach cells. Which factor is primarily associated with enterochromaffin-like (ECL) cells of the stomach, and how does it contribute to the patient's condition?</span></p>",
      "unique_key": "Q7115296",
      "question_audio": null,
      "question_video": null,
      "map_id": 4584734,
      "difficulty_level": "beginner",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:14.0pt;\"><strong>Ans. A) Histamine, which stimulates gastric acid production, potentially exacerbating ulcer symptoms.</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:14.0pt;\">Enterochromaffin-like (ECL) cells in the stomach are primarily involved in the secretion of histamine, which plays a crucial role in regulating gastric acid secretion by parietal cells.</span></li><li><span style=\"font-size:14.0pt;\">Histamine binds to H2 receptors on parietal cells, stimulating them to release more gastric acid. In conditions like chronic gastritis and peptic ulcer disease, excessive or unregulated acid production can exacerbate ulcer symptoms by further damaging the gastric or duodenal mucosa.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option B. Gastrin, which promotes mucus production and provides protection against ulcers:</strong> Gastrin is a hormone produced by G cells in the stomach, particularly in the antrum. It stimulates the secretion of gastric acid by parietal cells and promotes motility. Gastrin's role is not directly associated with ECL cells, but it can indirectly influence them by promoting histamine release, which then acts on parietal cells to increase acid secretion. However, gastrin itself does not promote mucus production for ulcer protection.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option C. Pepsinogen, an enzyme involved in protein digestion within the stomach:</strong> Pepsinogen is secreted by chief cells in the stomach and is the precursor to the enzyme pepsin, which is activated by gastric acid. Pepsin plays a critical role in the initial digestion of proteins in the stomach. While important for digestive processes, pepsinogen is not associated with ECL cells nor does it directly contribute to the protective mechanisms against ulcers.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option D. Secretin, a hormone that regulates pancreatic enzyme secretion, influencing digestion:</strong> Secretin is a hormone produced by S cells in the duodenum in response to acidic gastric contents entering the small intestine. It primarily functions to regulate the secretion of bicarbonate from the pancreas and bile ducts to neutralize stomach acid in the duodenum, protecting the intestinal lining and aiding in digestion. Secretin does not have a direct role in the stomach's function nor is it associated with ECL cells.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:14.0pt;\">In managing chronic gastritis and peptic ulcer disease, the histamine from ECL cells helps in stimulating gastric acid production by aggravating ulcer symptoms and increasing mucosal damage.</span></li><li><span style=\"font-size:14.0pt;\">Targeting this pathway with H2 receptor antagonists can be an effective strategy in reducing acid secretion and promoting ulcer healing.</span></li></ul>",
      "correct_choice_id": 163792,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41023,
      "choices": [
        {
          "id": 163796,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibrosis in and around the portal tracts </span></span></span></span></p>"
        },
        {
          "id": 163797,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombosis of the medium and small portal vein branches </span></span></span></span></p>"
        },
        {
          "id": 163798,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-specific inflammatory cell infiltrates in the portal tracts </span></span></span></span></p>"
        },
        {
          "id": 163799,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bridging fibrosis</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which one of the following is not a feature of liver histology in non-cirrhotic portal fibrosis?</span></span></span></span></p>",
      "unique_key": "Q3126917",
      "question_audio": null,
      "question_video": null,
      "map_id": 4584755,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Bridging fibrosis</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-cirrhotic portal fibrosis (NCPF) is characterized by fibrosis that is typically confined to the portal tracts and does not typically progress to bridging fibrosis or cirrhosis. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bridging fibrosis, which refers to fibrous tissue connecting the portal tracts to each other or to the central veins, is more commonly associated with chronic hepatitis and is a feature that suggests progression towards cirrhosis.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Fibrosis in and around the portal tracts</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a characteristic feature of NCPF, where the fibrosis is localized within the portal areas and does not typically extend beyond them. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Thrombosis of the medium and small portal vein branches</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This can occur in NCPF and is related to the obliteration of portal venules and can contribute to the portal hypertension observed in the disease. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Non-specific inflammatory cell infiltrates in the portal tracts</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Inflammation can be seen in NCPF but is generally mild and non-specific.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The key histologic feature of Non-cirrhotic portal fibrosis is fibrosis within the portal tracts, without the bridging fibrosis commonly associated with cirrhosis.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163799,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41026,
      "choices": [
        {
          "id": 163808,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil </span></span></span></span></p>"
        },
        {
          "id": 163809,
          "text": "<p>​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin </span></span></span></span></p>"
        },
        {
          "id": 163810,
          "text": "<p>​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carvedilol </span></span></span></span></p>"
        },
        {
          "id": 163811,
          "text": "<p>​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man with rheumatic mitral stenosis and atrial fibrillation is on therapy for a fast ventricular rate. While on treatment, he develops a regular pulse of 64 beats/min. Which of the following is the probable drug that the patient is receiving?</span></span></span></span></p>",
      "unique_key": "Q5927843",
      "question_audio": null,
      "question_video": null,
      "map_id": 4584828,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B)</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Digoxin</strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin is a cardiac glycoside that is particularly effective in controlling the ventricular rate in patients with atrial fibrillation, especially when complicated by heart failure, which might be present in a patient with rheumatic heart disease like mitral stenosis. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin slows the heart rate by increasing vagal (parasympathetic) tone and decreasing conduction through the atrioventricular (AV) node. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The regularity and controlled rate in this scenario are characteristic of the effects of digoxin, which can be profound in patients with atrial fibrillation by helping to convert an irregular, often fast pulse to a slower, more regular rhythm.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Verapamil</strong>: This is a calcium channel blocker also used to control heart rate in atrial fibrillation by reducing AV nodal conduction. However, it is less likely to be used in patients with mitral stenosis and signs of heart failure due to its negative inotropic effects (reducing the force of heart muscle contraction).</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Carvedilol</strong>: This is a beta-blocker with alpha-blocking activity, used for heart rate control and blood pressure reduction. While it can manage ventricular rate, its effects are not as specific in the setting of atrial fibrillation as digoxin, especially concerning the achievement of a regular rhythm.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Propranolol</strong>: Another beta-blocker, effective at reducing heart rate by blocking beta-adrenergic receptors, also affecting AV nodal conduction. Like carvedilol, it is used for rate control but does not typically convert the rhythm to regular as digoxin can.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with atrial fibrillation and underlying heart disease like mitral stenosis, digoxin is effective in controlling the ventricular rate by improving vagal tone and reducing AV nodal conduction, thus potentially regularizing the pulse.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163809,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41029,
      "choices": [
        {
          "id": 163820,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Temporal association</span></span></span></span></p>"
        },
        {
          "id": 163821,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Confounding bias</span></span></span></span></p>"
        },
        {
          "id": 163822,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Need for long follow-up</span></span></span></span></p>"
        },
        {
          "id": 163823,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Randomization</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In an epidemiological research, a nested case-control study is utilized within an ongoing cohort study. This design is particularly advantageous compared to a standard case-control study in addressing certain methodological challenges. Which of the following issues does a nested case-control study specifically help to avoid?</span></span></span></span></p>",
      "unique_key": "Q6048214",
      "question_audio": null,
      "question_video": null,
      "map_id": 4584851,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A) Temporal association</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The nested case-control study design is crucial for ensuring that the exposure precedes the outcome, thus establishing a clear temporal relationship. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This design selects cases (individuals who develop the outcome) and controls (those who do not) from participants who have already been followed forward in time within a cohort study. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, the exposure status is already known before the outcome occurs, which helps avoid the retrospective determination of exposure that plagues traditional case-control studies and can lead to temporal ambiguity.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Confounding bias:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While nested case-control studies can provide better adjustment for confounders due to pre-collected data, they do not inherently eliminate confounding bias compared to other study designs.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Need for long follow-up:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Nested case-control studies reduce the need for new long-term follow-up since they use pre-existing cohort data where follow-up has already been conducted. However, their primary strength over traditional case-control studies lies in their ability to clarify the temporal sequence.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Randomization:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Randomization is a method used in experimental designs, such as randomized controlled trials, to assign exposures or interventions. It is not typically a component of observational studies like case-control studies.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">NESTED CASE CONTROL STUDY</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"list-style-type: none;\">&nbsp;</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Is a hybrid design where &lsquo;a case control study is nested in a cohort study&rsquo;.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Is predominantly a type of Cohort study (due to forward direction).</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Usefulness limited for studies involving &lsquo;rare diseases AND whose diagnostic tests are very expensive&rsquo;.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163820,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41031,
      "choices": [
        {
          "id": 163828,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intravenous plasminogen activator</span></span></span></span></p>"
        },
        {
          "id": 163829,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unfractionated heparin</span></span></span></span></p>"
        },
        {
          "id": 163830,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombectomy</span></span></span></span></p>"
        },
        {
          "id": 163831,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IVC filter</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old female patient of nephrotic syndrome presents to the ER with complaints of acute onset of breathlessness after prolonged air travel for 16 hours. On clinical examination, pulse rate is 120/min with BP 130/80mm Hg. SpO2 is 85% and bedside echo shows right ventricular dilation with interventricular septum deviation to the left side. The next step in management is:</span></span></span></span></p>",
      "unique_key": "Q5004355",
      "question_audio": null,
      "question_video": null,
      "map_id": 4584923,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Unfractionated heparin</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initial management of a suspected acute Pulmonary Embolism (PE), especially in a hemodynamically unstable patient, involves anticoagulation. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unfractionated heparin has the advantage of rapid onset of action and can be reversed if necessary. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is the preferred initial treatment for PE in the emergency setting to prevent further clotting while further assessments and decisions regarding definitive therapy are made.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Intravenous plasminogen activator</strong>: This would be considered for massive PE with hemodynamic instability that is life-threatening, where thrombolysis is required urgently. If the patient&#39;s hypotension worsens, it could be considered at that point.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Thrombectomy</strong>: This is a surgical intervention or an interventional radiology procedure that is usually reserved for massive PE with hemodynamic collapse when thrombolytics are contraindicated or have failed, or for chronic, organized thrombi.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>IVC filter</strong>: Placement of an inferior vena cava (IVC) filter may be considered in patients with a contraindication to anticoagulation or in those who have had recurrent PE despite adequate anticoagulation. It&#39;s not the first-line treatment for an acute PE.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with suspected acute pulmonary embolism, the immediate management typically includes the initiation of anticoagulation therapy, with unfractionated heparin being a common choice due to its rapid onset and reversibility, appropriate for emergency settings.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163829,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41034,
      "choices": [
        {
          "id": 163840,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase A1</span></span></span></span></p>"
        },
        {
          "id": 163841,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase C</span></span></span></span></p>"
        },
        {
          "id": 163842,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase D</span></span></span></span></p>"
        },
        {
          "id": 163843,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase A2</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 26-year-old male was admitted after a snake bite. Soon after admission, he develops hematuria and deterioration in renal functions. Which enzyme in snake venom causes such effects?</span></span></span></span></p>",
      "unique_key": "Q1888957",
      "question_audio": null,
      "question_video": null,
      "map_id": 4584976,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">) Phospholipase A2</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase A2 (PLA2) is a common component of snake venoms, especially in viperidae and elapidae families. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PLA2 enzymes hydrolyze the sn-2 position of phospholipids, leading to the production of arachidonic acid and lysophospholipids. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This action can disrupt cell membranes, affect blood coagulation pathways, and lead to inflammation, which can contribute to hematuria (blood in urine) and renal dysfunction following a snakebite. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The renal effects can be due to direct nephrotoxicity, hemoglobinuria secondary to hemolysis, or disseminated intravascular coagulation (DIC) complicating severe envenomation.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Phospholipase A1</strong>: This enzyme acts on the sn-1 position of the glycerol backbone in phospholipids, releasing a fatty acid. While phospholipase A1 is present in some snake venoms, it is not as commonly implicated in causing systemic toxic effects such as hematuria and renal dysfunction as Phospholipase A2.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Phospholipase C</strong>: Phospholipase C (PLC) hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into two secondary messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which play roles in cellular signaling pathways. Although PLC can be a component of some snake venoms and contribute to their overall toxicity, it is not specifically known for causing the acute renal effects and hematuria seen in envenomation cases.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Phospholipase D</strong>: Phospholipase D (PLD) hydrolyzes phosphatidylcholine to produce phosphatidic acid and choline. While PLD is found in some organisms and can have toxic effects, it is not typically associated with snake venoms or the specific renal and urinary manifestations seen in snakebite victims.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PLA2 is known for its role in snake venoms, particularly in causing systemic and local effects due to its enzymatic activity on phospholipids, leading to cell membrane disruption, inflammation, and interference with hemostasis, which can contribute to hematuria and renal dysfunction.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163843,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41036,
      "choices": [
        {
          "id": 163848,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dorsal group of neurons</span></span></span></span></p>"
        },
        {
          "id": 163849,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ventral group of neurons</span></span></span></span></p>"
        },
        {
          "id": 163850,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumotaxic center</span></span></span></span></p>"
        },
        {
          "id": 163851,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chemoreceptors</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following neurons predominantly fire during forceful expiration?</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>",
      "unique_key": "Q5527124",
      "question_audio": null,
      "question_video": null,
      "map_id": 4585068,
      "difficulty_level": "intermediate",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B) Ventral group of neurons</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The ventral respiratory group (VRG) of neurons, located in the medulla, is primarily involved in active or forceful breathing, both inspiration and expiration. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During forceful expiration, the VRG activates expiratory muscles, such as the internal intercostal muscles and the abdominal muscles, to increase the pressure in the thoracic cavity and forcibly expel air from the lungs.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Dorsal group of neurons:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The dorsal respiratory group (DRG), also located in the medulla, is primarily involved in the basic rhythm of breathing and mainly controls the diaphragm, the primary muscle for inspiration. The DRG is more active during quiet, restful breathing and does not predominantly fire during forceful expiration.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Pneumotaxic center:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The pneumotaxic center, located in the upper pons, helps regulate the rate and pattern of breathing. It primarily modulates the switch from inspiration to expiration by limiting the activity of inspiratory neurons, thus controlling the duration of inspiration and influencing the respiratory rate. However, it is not directly responsible for forceful expiration.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Chemoreceptors:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Chemoreceptors, including central chemoreceptors in the medulla and peripheral chemoreceptors in the carotid and aortic bodies, detect changes in blood levels of carbon dioxide, oxygen, and pH. They provide input to the respiratory centers to adjust ventilation to meet the body&#39;s metabolic demands. While they play a crucial role in the overall regulation of respiration, they do not directly fire during forceful expiration.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In managing patients with respiratory distress or during procedures requiring assisted ventilation, the ventral respiratory group of neurons is primarily responsible for forceful expiration.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163849,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41039,
      "choices": [
        {
          "id": 163860,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha-fetoprotein </span></span></span></span></p>"
        },
        {
          "id": 163861,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bombesin </span></span></span></span></p>"
        },
        {
          "id": 163862,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CA-125 </span></span></span></span></p>"
        },
        {
          "id": 163863,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PSA </span></span><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Prostate-Specific Antigen)</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral ovarian masses are identified on pelvic examination of a 40-year-old woman for which she undergoes total abdominal hysterectomy. Pathologic examination demonstrates papillary carcinoma producing serous fluid. Which of the following tumor markers would be most useful in monitoring for recurrence?</span></span></span></span></p>",
      "unique_key": "Q6458442",
      "question_audio": null,
      "question_video": null,
      "map_id": 4585121,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) CA-125</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CA-125 is a tumor marker that is often elevated in women with ovarian cancer, especially in those with epithelial ovarian cancers such as serous carcinoma. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is useful for monitoring treatment response and detecting recurrence in patients with epithelial ovarian cancer.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Alpha-fetoprotein</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This tumor marker is more commonly associated with liver cancer (hepatocellular carcinoma) and germ cell tumors of the ovary, not typically with epithelial ovarian cancers like serous carcinoma. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Bombesin</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is not a standard tumor marker for monitoring ovarian cancer. It has been studied in various cancers but is not routinely used in clinical practice for ovarian cancer. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. PSA (Prostate-Specific Antigen)</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: PSA is a tumor marker used primarily to screen for and monitor prostate cancer in men. It is not used for ovarian cancer.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CA-125 is the most useful tumor marker for monitoring treatment response and recurrence in patients with epithelial ovarian cancer, such as serous carcinoma.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163862,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41042,
      "choices": [
        {
          "id": 163872,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone </span></span></span></span></p>"
        },
        {
          "id": 163873,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Eplerenone </span></span></span></span></p>"
        },
        {
          "id": 163874,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrochlorothiazide </span></span></span></span></p>"
        },
        {
          "id": 163875,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiloride</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which diuretic could be considered appropriate for combining with ACE inhibitors?</span></span></span></span></p>",
      "unique_key": "Q4179487",
      "question_audio": null,
      "question_video": null,
      "map_id": 4585274,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">) Hydrochlorothiazide</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrochlorothiazide, a thiazide diuretic, is commonly combined with ACE inhibitors in the treatment of hypertension. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This combination is effective because hydrochlorothiazide reduces plasma volume by promoting sodium and water excretion, which complements the effects of ACE inhibitors. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACE inhibitors reduce the formation of angiotensin II, leading to vasodilation and further reduction in blood pressure. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Additionally, the combination can help counteract the potassium retention that can occur with ACE inhibitor use, as thiazide diuretics tend to promote potassium excretion.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A) Spironolactone and Option B) Eplerenone:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Both are potassium-sparing diuretics that inhibit aldosterone&#39;s action. When used with ACE inhibitors, there is an increased risk of hyperkalemia (high potassium levels), which can be dangerous. Therefore, while these can be used carefully in certain clinical situations such as heart failure, they require careful monitoring of potassium levels.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D) Amiloride:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Also, </span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> a potassium-sparing diuretic, similar to spironolactone and eplerenone, amiloride can increase the risk of hyperkalemia when combined with ACE inhibitors and is generally not the first choice unless specifically indicated and closely monitored.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The rationale for combining hydrochlorothiazide, a thiazide diuretic, with ACE inhibitors in the management of hypertension not only enhances blood pressure control but also balances the potassium-sparing effects of ACE inhibitors with the potassium-excreting properties of thiazide diuretics, minimizing the risk of hyperkalemia.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163874,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41043,
      "choices": [
        {
          "id": 163876,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Controls should be selected from a population that has the same potential for glioma as the cases. </span></span></span></span></p>"
        },
        {
          "id": 163877,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Controls should exclude individuals known to be exposed to high levels of electromagnetic fields at the time of the survey.</span></span></span></span></p>"
        },
        {
          "id": 163878,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Controls need to be free from glioma but not necessarily from other non-related health conditions. </span></span></span></span></p>"
        },
        {
          "id": 163879,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The attributable risk of glioma resulting from electromagnetic field exposure may be directly measured.</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A case-control study is designed to investigate the potential association between long-term exposure to electromagnetic fields and the development of glioma. Researchers are determining which statements about the selection of controls and the study design are accurate. Which of the following statements is incorrect?</span></span></span></span></p>",
      "unique_key": "Q1098244",
      "question_audio": null,
      "question_video": null,
      "map_id": 4585395,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D) The attributable risk of glioma resulting from electromagnetic field exposure may be directly measured.</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a case-control study, attributable risk, which quantifies the increased risk of a disease due to an exposure within the population, cannot be directly measured. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is because case-control studies are inherently retrospective and primarily designed to calculate odds ratios rather than incidence rates. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Attributable risk is more accurately determined through prospective cohort studies where the incidence of disease in exposed and unexposed groups can be observed over time.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Controls should be selected from a population that has the same potential for glioma as the cases.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is correct because it ensures that any difference in the disease incidence between the groups can more likely be attributed to the exposure rather than other factors.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Controls should exclude individuals known to be exposed to high levels of electromagnetic fields at the time of the survey.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement might be considered during the study design to control for confounding, but it could also bias the selection of controls.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Controls need to be free from glioma but not necessarily from other non-related health conditions.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is true, as controls are selected to provide a comparison for the exposure status and disease outcome, not their overall health status.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"list-style-type: none;\">&nbsp;</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AR calculation requires incidence which can be obtained from only a cohort study (Not from a case control study).</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a Case Control Study, &lsquo;Cases&rsquo; are diseased and &lsquo;Controls&rsquo; are healthy.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Controls should be similar to Cases in all respects (for ensuring comparability).</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cases should be matched with controls for all factors &lsquo;EXCEPT for the (risk) factor under study&rsquo; (otherwise the etiological role of risk factor under study, which we are studying, would be eliminated from the study, since both groups are exactly similar in all respects). </span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163879,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41044,
      "choices": [
        {
          "id": 163880,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Portal Hypertension </span></span></span></span></p>"
        },
        {
          "id": 163881,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gastric ulcer </span></span></span></span></p>"
        },
        {
          "id": 163882,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug-induced </span></span></span></span></p>"
        },
        {
          "id": 163883,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mallory Weiss Tear</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A man presents with a history of hematemesis of about 500 ml of blood. On examination, the spleen is palpable 5 cms below the left costal margin. The most likely diagnosis is:</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>",
      "unique_key": "Q3814000",
      "question_audio": null,
      "question_video": null,
      "map_id": 4585516,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Portal Hypertension</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of hematemesis (vomiting of blood) and palpable splenomegaly (enlarged spleen) suggests portal hypertension as the most likely diagnosis. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Portal hypertension can lead to the development of varices in the stomach and esophagus, which can rupture and cause significant bleeding as described in this scenario.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Gastric ulcer</strong>: While a gastric ulcer can cause hematemesis, it is less likely to be associated with splenomegaly unless there is an underlying chronic liver disease leading to portal hypertension.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Drug-induced</strong>: Drug-induced hematemesis is possible, especially with the use of NSAIDs or other medications that can cause gastric irritation or ulceration, but it typically does not cause splenomegaly.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Mallory Weiss Tear</strong>: A Mallory-Weiss tear can cause hematemesis, often following severe retching, but it does not explain the spleen enlargement noted on examination.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with hematemesis and splenomegaly, portal hypertension should be considered the most likely diagnosis. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The condition can lead to the formation of varices, which are prone to rupture and can cause significant gastrointestinal bleeding.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163880,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41045,
      "choices": [
        {
          "id": 163884,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tyrosine</span></span></span></span></p>"
        },
        {
          "id": 163885,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lysine</span></span></span></span></p>"
        },
        {
          "id": 163886,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leucine</span></span></span></span></p>"
        },
        {
          "id": 163887,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspartate</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following can be converted to an intermediate of either the citric acid cycle or the urea cycle?</span></span></span></span></p>",
      "unique_key": "Q3577519",
      "question_audio": null,
      "question_video": null,
      "map_id": 4585777,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Aspartate</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspartate plays a crucial role in both the citric acid cycle and the urea cycle. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the citric acid cycle, aspartate can be transaminated to oxaloacetate, a key intermediate. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the urea cycle, aspartate combines with citrulline to form argininosuccinate, which is later cleaved to form arginine and fumarate, the latter of which can enter the citric acid cycle. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, aspartate links amino acid metabolism with the citric acid and urea cycles, making it integral to both energy production and nitrogen disposal.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Tyrosine</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Tyrosine is a non-essential amino acid that is involved in various pathways, including the synthesis of neurotransmitters and hormones. It is not directly converted into an intermediate of the citric acid or urea cycles.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Lysine</strong>: Lysine is an essential amino acid that plays roles in protein synthesis, hormone production, and calcium absorption. It is not directly converted into an intermediate of the citric acid or urea cycles.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Leucine</strong>: Leucine is an essential branched-chain amino acid involved in protein synthesis and various signalling pathways. It is known for its role in stimulating muscle protein synthesis but does not directly convert into an intermediate of the citric acid or urea cycles.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspartate is unique among amino acids for its ability to be converted into intermediates of both the citric acid cycle (as oxaloacetate) and the urea cycle, linking nitrogen metabolism with energy production pathways. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This highlights the interconnectedness of metabolic pathways in the body.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163887,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41047,
      "choices": [
        {
          "id": 163888,
          "text": "<p><span style=\"font-size:14.0pt;\">Chromosome painting</span></p>"
        },
        {
          "id": 163889,
          "text": "<p><span style=\"font-size:14.0pt;\">Fluorescence in situ hybridization (FISH)</span></p>"
        },
        {
          "id": 163890,
          "text": "<p>​​​​​<span style=\"font-size:14.0pt;\">Comparative genomic hybridization</span></p>"
        },
        {
          "id": 163891,
          "text": "<p><span style=\"font-size:14.0pt;\">Western blot</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:14.0pt;\">Which of the following techniques can be used to detect exact localisation of a genetic locus?</span></p>",
      "unique_key": "Q3418384",
      "question_audio": null,
      "question_video": null,
      "map_id": 4586128,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:14.0pt;\"><strong>Ans. B) Fluorescence in situ hybridization (FISH)</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:14.0pt;\">Fluorescence in situ hybridization (FISH) is a technique that can be used to detect and localize the presence or absence of specific DNA sequences on chromosomes.</span></li><li><span style=\"font-size:14.0pt;\">FISH uses fluorescent probes that bind to only those parts of the chromosome with a high degree of sequence complementarity.</span></li><li><span style=\"font-size:14.0pt;\">It is a powerful technique for identifying chromosomal abnormalities and for mapping genetic material.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option A. Chromosome painting</strong>: This technique involves labelling each chromosome with a different fluorescent dye. It is useful for identifying structural abnormalities in chromosomes but does not provide exact localization of a genetic locus.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option C. Comparative genomic hybridization</strong>: This technique is used to detect and map changes in DNA copy number variations across the genome. It compares the DNA content of a test sample to a reference sample to identify gains and losses of genomic material but does not provide precise localization of specific loci.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option D. Western blot</strong>: This technique is used for the detection and analysis of proteins. It involves separating proteins by gel electrophoresis, transferring them to a membrane, and detecting them using antibodies. It is not used for localizing genetic loci.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:14.0pt;\">FISH (Fluorescence in situ hybridization) is the preferred technique for detecting the exact localization of specific genetic loci on chromosomes, as it allows for direct visualization of fluorescently labelled DNA probes bound to chromosomal DNA.</span></li></ul>",
      "correct_choice_id": 163889,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41050,
      "choices": [
        {
          "id": 163900,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liothyronine </span></span></span></span></p>"
        },
        {
          "id": 163901,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol</span></span></span></span></p>"
        },
        {
          "id": 163902,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methimazole </span></span></span></span></p>"
        },
        {
          "id": 163903,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Potassium iodide solution</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is used to control tachycardia and palpitations in persons with acute symptoms of hyperthyroidism?</span></span></span></span></p>",
      "unique_key": "Q1171324",
      "question_audio": null,
      "question_video": null,
      "map_id": 4586191,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B)</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Propranolol</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol is a non-selective beta-blocker commonly used to control heart rate and reduce symptoms such as tachycardia and palpitations in patients with hyperthyroidism. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is effective in providing symptomatic relief by blocking the beta-adrenergic receptors, which are often overly stimulated due to high levels of circulating thyroid hormones. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol also has the additional benefit of inhibiting the peripheral conversion of T4 to the more active T3, thus providing some degree of control over thyroid hormone activity.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Liothyronine</strong>: This is a synthetic form of the thyroid hormone T3 and would exacerbate symptoms of hyperthyroidism, not control them.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Methimazole</strong>: While methimazole is used to reduce thyroid hormone production in hyperthyroidism, it does not provide the immediate symptom control needed for acute symptoms like tachycardia and palpitations.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Potassium iodide solution</strong>: Potassium iodide is used in thyroid storm or prior to surgery to decrease the size and vascularity of the thyroid gland but is not specifically used for immediate control of tachycardia and palpitations.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol is the drug of choice for managing acute cardiovascular symptoms such as tachycardia and palpitations in hyperthyroidism due to its rapid onset of action in blocking sympathetic overactivity induced by high levels of thyroid hormones.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163901,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41052,
      "choices": [
        {
          "id": 163908,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CONSORT &ndash; Randomized Controlled Trials (RCT) </span></span></span></span></p>"
        },
        {
          "id": 163909,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MOOSE &ndash; Meta-analysis of Observational Studies </span></span></span></span></p>"
        },
        {
          "id": 163910,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CARE &ndash; Randomized Controlled Trials (RCT) </span></span></span></span></p>"
        },
        {
          "id": 163911,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRISMA &ndash; Systematic Review and Meta-analysis</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In reviewing guidelines for various types of research studies, a medical researcher comes across several standardized reporting guidelines each aimed at improving the quality and transparency of research. Which of the following pairings of guidelines and study types is incorrectly matched?</span></span></span></span></p>",
      "unique_key": "Q4667216",
      "question_audio": null,
      "question_video": null,
      "map_id": 4586313,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C) CARE &ndash; Randomized Controlled Trials (RCT)</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The CARE (Case Report) guidelines are specifically designed for case reports, not randomized controlled trials (RCTs). </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CARE aims to improve the accuracy and detail in reporting case reports, which are detailed presentations of a single patient&#39;s medical story.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. CONSORT (Consolidated Standards of Reporting Trials):</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This guideline is correctly matched with Randomized Controlled Trials (RCTs). CONSORT is intended to standardize and improve the quality of reporting in RCTs.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. MOOSE (Meta-analysis Of Observational Studies in Epidemiology):</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is accurately matched with the Meta-analysis of Observational Studies. MOOSE provides a framework for reporting findings in research that involves meta-analysis of observational studies.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses):</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is correctly paired with Systematic Review and Meta-analysis. PRISMA is a widely recognized protocol for reporting systematic reviews and meta-analyses, aiming to enhance clarity and transparency.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">GUIDELINES FOR REPORTING MEDICAL RESEARCH</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"list-style-type:none\">&nbsp;</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CONSORT (Consolidated Standards of Reporting Trials)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MOOSE (Meta-analysis Of Observational Studies in Epidemiology) </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">STROBE (STrengthening the Reporting of Observational studies in Epidemiology) </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">STARD (STAndards for the Reporting of Diagnostic accuracy studies) </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CARE guidelines were developed by an international group of experts to increase the accuracy, transparency, and usefulness of case reports</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163910,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41055,
      "choices": [
        {
          "id": 163920,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic hepatitis B infection with high infectivity </span></span></span></span></p>"
        },
        {
          "id": 163921,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute hepatitis B infection with high infectivity </span></span></span></span></p>"
        },
        {
          "id": 163922,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic hepatitis B infection with low infectivity </span></span></span></span></p>"
        },
        {
          "id": 163923,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute hepatitis B infection with low infectivity</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old man presented with nausea, fever, and jaundice of 5 days duration. The biochemical tests revealed a bilirubin of 6.7 mg/dl, unconjugated bilirubin of 5.0 mg/dl with SGOT/SGPT (AST/ALT) of 1230/900 IU/ml. The serological tests showed the presence of HBsAg IgM, anti HBc and HBeAg. The most likely diagnosis is:</span></span></span></span></p>",
      "unique_key": "Q5574039",
      "question_audio": null,
      "question_video": null,
      "map_id": 4586366,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Acute hepatitis B infection with high infectivity</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of IgM antibody to HBsAg typically indicates an acute infection with hepatitis B. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The high levels of liver enzymes (SGOT/SGPT) support active liver inflammation. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Additionally, the presence of HBeAg is a marker of high infectivity and active viral replication. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This serological profile is consistent with an acute hepatitis B infection, not a chronic one.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Chronic hepatitis B infection with high infectivity</strong>: Chronic infection is indicated by the presence of HBsAg for more than 6 months. The presence of IgM HBc antibody is more indicative of a recent, acute infection.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Chronic hepatitis B infection with low infectivity</strong>: This would typically be indicated by the presence of anti-HBe rather than HBeAg, and there would not typically be a presentation of acute hepatitis symptoms.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Acute hepatitis B infection with low infectivity</strong>: If HBeAg were negative and anti-HBe were positive, this might suggest a lower infectivity, but the patient&#39;s profile suggests high infectivity.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of IgM HBsAg along with elevated liver enzymes and HBeAg in a patient presenting with symptoms of acute hepatitis is diagnostic of acute hepatitis B infection with high infectivity. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The diagnosis is based on serological profiles, which distinguish acute from chronic infections and determine infectivity based on the presence of HBeAg.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163921,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41058,
      "choices": [
        {
          "id": 163932,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pheochromocytoma </span></span></span></span></p>"
        },
        {
          "id": 163933,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary carcinoma thyroid </span></span></span></span></p>"
        },
        {
          "id": 163934,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphoma </span></span></span></span></p>"
        },
        {
          "id": 163935,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal cell carcinoma</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman presents to her primary care physician with a palpable lump in her neck and symptoms of weight loss, tremors, and palpitations. Physical examination reveals a firm, non-tender mass in the anterior neck region. Ultrasonography confirms the presence of a thyroid nodule. Genetic testing reveals a mutation in the RET gene. This&nbsp;</span></span><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">gene mutation is associated with which malignancy?</span></span></span></span></p>",
      "unique_key": "Q1544358",
      "question_audio": null,
      "question_video": null,
      "map_id": 4586739,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Medullary carcinoma thyroid</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The RET gene mutation is closely associated with medullary carcinoma of the thyroid. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor originating from the parafollicular C cells of the thyroid gland. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RET gene mutations can be both somatic and germline. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Germline mutations of the RET proto-oncogene are also linked to multiple endocrine neoplasia type 2 (MEN2) syndromes, which include MTC as a prominent feature.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pheochromocytoma</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While pheochromocytomas are associated with multiple endocrine neoplasia type 2 (MEN2) syndromes, which involve RET gene mutations, the tumors themselves are not directly caused by RET mutations but rather are a part of the syndrome. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Lymphoma</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: There is no direct association between RET gene mutations and lymphomas. Lymphomas are cancers of the lymphatic system and have different genetic associations. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Renal cell carcinoma</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: RET gene mutations are not directly associated with renal cell carcinoma. Renal cell carcinoma, a type of kidney cancer, has different genetic risk factors, including mutations in the VHL gene among others.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary carcinoma of the thyroid is closely associated with mutations in the RET gene, which plays a crucial role in cell growth and development. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These mutations can lead to uncontrolled cell growth and the development of medullary thyroid carcinoma.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163933,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41062,
      "choices": [
        {
          "id": 163948,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It acts by inhibiting the enzyme alpha-glucosidase </span></span></span></span></p>"
        },
        {
          "id": 163949,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It reduces post-prandial hyperglycemia </span></span></span></span></p>"
        },
        {
          "id": 163950,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It decreases the progression of impaired glucose tolerance to overt diabetes mellitus </span></span></span></span></p>"
        },
        {
          "id": 163951,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can cause hypoglycemia</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements regarding acarbose is FALSE?</span></span></span></span></p>",
      "unique_key": "Q3605389",
      "question_audio": null,
      "question_video": null,
      "map_id": 4586813,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) It can cause hypoglycemia</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acarbose works by inhibiting the enzyme alpha-glucosidase in the intestines, which delays the digestion of ingested carbohydrates, thereby reducing the rise in blood glucose levels after meals (postprandial hyperglycemia). </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This mechanism generally does not lead to hypoglycemia because acarbose does not stimulate insulin secretion directly. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoglycemia is typically not a direct effect of acarbose unless it is combined with other antidiabetic medications such as sulfonylureas or insulin.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>It acts by inhibiting the enzyme alpha-glucosidase</strong>: This is true. Acarbose inhibits alpha-glucosidase in the small intestine, slowing carbohydrate digestion and absorption.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>It reduces post-prandial hyperglycemia</strong>: This is true. By inhibiting carbohydrate digestion, acarbose helps to lower the rise in blood glucose that occurs after eating.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>It decreases the progression of impaired glucose tolerance to overt diabetes mellitus</strong>: This is true. Acarbose has been shown to help prevent the progression from prediabetes to type 2 diabetes by managing postprandial blood glucose levels and improving overall glycemic control.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acarbose, an alpha-glucosidase inhibitor, effectively reduces postprandial hyperglycemia by delaying carbohydrate digestion and absorption. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It does not cause hypoglycemia by itself as it does not influence insulin secretion directly.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163951,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41065,
      "choices": [
        {
          "id": 163960,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1-2 doses </span></span></span></span></p>"
        },
        {
          "id": 163961,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Single dose </span></span></span></span></p>"
        },
        {
          "id": 163962,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2 doses </span></span></span></span></p>"
        },
        {
          "id": 163963,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3 doses</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">According to the World Health Organization&#39;s Strategic Advisory Group of Experts (WHO-SAGE) on immunization recommendations for Human Papillomavirus (HPV) vaccination in the 9-14 years age group, what is the correct dosing schedule?</span></span></span></span></p>",
      "unique_key": "Q8018833",
      "question_audio": null,
      "question_video": null,
      "map_id": 4586886,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A) 1-2 doses</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SAGE recommends updating dose schedules for HPV.</span></span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">One or two-dose schedule for the primary target of girls aged 9-14</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">One or two-dose schedule for young women aged 15-20 </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Two doses with a 6-month interval for women older than 21</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The WHO-SAGE guidelines recommend a flexible dosing schedule for the HPV vaccine in the 9-14 years age group, which can be either a single dose or a two-dose regimen. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recent evidence supports the effectiveness of a single-dose schedule in providing adequate protection against HPV infections, prompting considerations for this as a feasible and effective option.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163960,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41070,
      "choices": [
        {
          "id": 163980,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Total capacity</span></span></span></span></p>"
        },
        {
          "id": 163981,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1</span></span></span></span></p>"
        },
        {
          "id": 163982,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FVC</span></span></span></span></p>"
        },
        {
          "id": 163983,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flow-volume loop</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following parameters cannot be obtained by using the following instrument?</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/16/picture7_e5OizuH.jpg\" style=\"height:330px; width:300px\" /></span></span></span></span></p>",
      "unique_key": "Q5819604",
      "question_audio": null,
      "question_video": null,
      "map_id": 4586891,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Total capacity</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The instrument shown in the image is a spirometer. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used to measure various parameters of lung function, most notably those involving the movement of air in and out of the lungs under specific conditions and time constraints. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Total lung capacity (TLC) cannot be measured directly by a spirometer because it includes the residual volume (RV), which is the amount of air remaining in the lungs after a full, forceful exhalation and cannot be measured by forced expiration. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To measure TLC, additional techniques such as body plethysmography or gas dilution are required.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>FEV1:</strong> Forced Expiratory Volume in 1 second can be measured by a spirometer. It reflects the volume of air that can be forcefully blown out in one second, after full inspiration, and is a critical measure for assessing conditions like asthma and COPD.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>FVC:</strong> Forced Vital Capacity can be measured by a spirometer and represents the total volume of air that can be forcefully exhaled after full inspiration. It is used to evaluate lung function and to identify obstructive versus restrictive lung disease patterns.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Flow-volume loop:</strong> This graphical representation depicts the rate of airflow (on the y-axis) versus the total volume of air exhaled (on the x-axis) during a forceful respiratory manoeuvre. Spirometers are capable of generating flow-volume loops, which help in the diagnosis and assessment of lung diseases.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The spirometry can measure dynamic lung volumes and capacities such as FEV1, FVC, and provide a flow-volume loop, which are essential for the diagnosis and management of respiratory diseases.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163980,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41071,
      "choices": [
        {
          "id": 163984,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased B cell count </span></span></span></span></p>"
        },
        {
          "id": 163985,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased B cell count </span></span></span></span></p>"
        },
        {
          "id": 163986,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal B cell count </span></span></span></span></p>"
        },
        {
          "id": 163987,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Absent B cells</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a finding in lymphoid tissues in individuals with common variable hypogammaglobulinemia?</span></span></span></span></p>",
      "unique_key": "Q4284165",
      "question_audio": null,
      "question_video": null,
      "map_id": 4586943,
      "difficulty_level": "difficult",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Normal B cell count</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In individuals with Common Variable Immunodeficiency (CVID), the lymphoid tissues often show a normal B cell count. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Despite the normal quantity of B cells, there is an impairment in the differentiation or function of these cells, leading to decreased levels of serum immunoglobulins (hypogammaglobulinemia) and increased susceptibility to infections. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of normal B cell numbers with impaired function is a characteristic finding in CVID.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Decreased B cell count</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While some forms of immunodeficiency, such as X-linked agammaglobulinemia, are characterized by decreased B cell counts, CVID typically presents with normal B cell counts in lymphoid tissues. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Increased B cell count</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: An increased B cell count is not characteristic of CVID. Some other conditions may show lymphoid hyperplasia, but in CVID, the issue is more related to B cell function rather than quantity. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Absent B cells</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Complete absence of B cells is not typical of CVID and is more indicative of more severe forms of immunodeficiency, such as X-linked agammaglobulinemia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Common Variable Immunodeficiency (CVID) is an immunodeficiency disorder where individuals typically have a normal B cell count in lymphoid tissues, but the B cells have impaired function. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This leads to decreased immunoglobulin levels and an increased susceptibility to infections.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163986,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41074,
      "choices": [
        {
          "id": 163996,
          "text": "<p>​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stop the drug and start another antiepileptic </span></span></span></span></p>"
        },
        {
          "id": 163997,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Taper the drug over 6 months </span></span></span></span></p>"
        },
        {
          "id": 163998,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continue the medication for another 3 years </span></span></span></span></p>"
        },
        {
          "id": 163999,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decrease the dose of levetiracetam</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An epileptic adult man is on levetiracetam 1 g twice a day therapy. He is seizure free for 2 years. Now, he started developing irritability, aggression and liability of mood that is affecting his daily life. What should the doctor do?</span></span></span></span></p>",
      "unique_key": "Q7002602",
      "question_audio": null,
      "question_video": null,
      "map_id": 4587045,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B)</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Taper the drug over 6 months</strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gradually tapering the dose of levetiracetam is a sensible approach when the patient starts showing significant behavioral side effects that are impacting daily life. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This gradual reduction can help to minimize the risk of seizure recurrence while potentially alleviating the adverse mood effects associated with the drug. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The decision to taper should be carefully monitored, and alternative antiepileptic drugs should be considered if seizure control becomes insufficient or if mood disturbances persist or worsen.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Stop the drug and start another antiepileptic</strong>: Abruptly stopping an antiepileptic drug can lead to seizure recurrence. Transitioning to another medication should be done carefully with an overlap period or taper to ensure continuous seizure control.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Continue the medication for another 3 years</strong>: Continuing the medication without addressing the significant side effects is not advisable as it neglects the impact on the patient&#39;s mental health and quality of life.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Decrease the dose of levetiracetam</strong>: While decreasing the dose may potentially reduce side effects, it may not adequately address the severity of the mood changes, and there&#39;s a risk that it might not maintain seizure control. A thorough evaluation and possibly switching to another medication might be required, which needs careful planning.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When managing side effects of antiepileptic drugs, especially behavioral or psychological side effects, a careful balance must be maintained between controlling seizures and managing adverse effects. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tapering the medication gradually under close medical supervision is often the safest approach to modifying treatment, allowing for adjustment of therapy based on the patient&#39;s response in terms of both seizure control and side effect profile.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 163997,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41076,
      "choices": [
        {
          "id": 164000,
          "text": "<p>​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Change in the colour of the vaccine </span></span></span></span></p>"
        },
        {
          "id": 164001,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Temperature indicator of the system </span></span></span></span></p>"
        },
        {
          "id": 164002,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Viral potency test </span></span></span></span></p>"
        },
        {
          "id": 164003,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Change in the colour of the monitor</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A clinic in a remote area relies on the Vaccine Vial Monitor (VVM) to ensure the usefulness of vaccine during transport and storage. The VVM is an essential component of the cold chain system. What does the effectiveness of the VVM in monitoring the integrity of the vaccine depend on?</span></span></span></span></p>",
      "unique_key": "Q5030807",
      "question_audio": null,
      "question_video": null,
      "map_id": 4587246,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D) Change in the color of the monitor</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Vaccine Vial Monitor (VVM) is specifically designed to react chemically to heat exposure over time, which results in a color change in the monitor itself. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This color change indicates whether the vaccine has been stored under conditions that maintain its effectiveness or if it has been exposed to heat levels that could potentially degrade its potency. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The VVM&#39;s visual indicator allows healthcare providers to easily determine the vaccine&#39;s viability before use.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/16/picture10_EenOYn9.jpg\" style=\"height:157px; width:700px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Change in the color of the vaccine:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The vaccine&#39;s color does not serve as an indicator for temperature exposure or vaccine efficacy; thus, this option is incorrect.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Temperature indicator of the system:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While overall temperature monitoring is part of the cold chain system, the VVM&#39;s functionality is not a direct temperature display but rather a chemical response to heat exposure reflected through a color change.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Viral potency test:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Although this test measures the actual potency of the virus in the vaccine in a lab setting, it is not practical for ongoing, field-based monitoring and does not relate directly to the function of the VVM.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">WHO grading of VVM</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Marker of potency is based on colour changes in VVM: only inner square changes colour, circle always remain blue. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VVM has been introduced for almost all vaccines (in NIS) too in India.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In VVM, &lsquo;direct relationship exists between the rate of colour change and temperature&rsquo;, the lower the temperature, the slower the colour change &ndash; The higher the temperature, the faster the colour change.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rules for VVM use in India:</span></span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rule 1</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: If the inner square is lighter than the outer circle, the vaccine may be used&ndash;</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rule 2</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: If the inner square is the same colour as, or darker than, the outer circle, the vaccine must not be used</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The VVM inner square start point colour is approximately 10% of the outer circle colour.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Validation of VVMs</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Optical densitometer (for colour density measurement)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VVM is best interpreted on a nominal scale: Usable or non-usable</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164003,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41077,
      "choices": [
        {
          "id": 164004,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antiendomysial antibodies </span></span></span></span></p>"
        },
        {
          "id": 164005,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-goblet cell antibodies </span></span></span></span></p>"
        },
        {
          "id": 164006,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-Saccharomyces cerevisiae antibodies </span></span></span></span></p>"
        },
        {
          "id": 164007,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antineutrophil cytoplasmic antibodies</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old lady presents with features of malabsorption and iron deficiency anemia. Duodenal biopsy shows complete villous atrophy. Probable diagnosis is:</span></span></span></span></p>",
      "unique_key": "Q9586855",
      "question_audio": null,
      "question_video": null,
      "map_id": 4588228,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Antiendomysial antibodies</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antiendomysial antibodies (EMA) are highly specific for celiac disease and are often used to confirm the diagnosis in conjunction with clinical presentation and histological findings from intestinal biopsy, such as complete villous atrophy.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Anti-goblet cell antibodies</strong>: These are not typically associated with celiac disease or known to be a standard marker for any particular gastrointestinal disorder.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Anti-Saccharomyces cerevisiae antibodies (ASCA)</strong>: These are associated with Crohn&#39;s disease and other forms of inflammatory bowel disease, not typically celiac disease.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Antineutrophil cytoplasmic antibodies (ANCA)</strong>: These are associated with vasculitis and inflammatory bowel diseases, particularly ulcerative colitis, not celiac disease.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of malabsorption and duodenal biopsy findings of complete villous atrophy, the most likely diagnosis is celiac disease, and the corresponding serological test would be antiendomysial antibodies, which have a high specificity for this condition.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164004,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41080,
      "choices": [
        {
          "id": 164016,
          "text": "<p>​​​​​<span style=\"font-size:14.0pt;\">Lymphocytic pleocytosis, low sugar, low protein</span></p>"
        },
        {
          "id": 164017,
          "text": "<p>​​​​​​<span style=\"font-size:14.0pt;\">Polymorphonuclear pleocytosis, normal sugar, high protein</span></p>"
        },
        {
          "id": 164018,
          "text": "<p>​​​​​​<span style=\"font-size:14.0pt;\">Lymphocytic pleocytosis, low sugar, high protein</span></p>"
        },
        {
          "id": 164019,
          "text": "<p>​​​​​​<span style=\"font-size:14.0pt;\">Lymphocytic pleocytosis, normal sugar, high protein</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">A 17-year-old female presents with a history of fever and headache and now develops altered sensorium. CT scan shows basal exudates with meningeal enhancement. The CSF is most likely to show:</span></p>",
      "unique_key": "Q1234330",
      "question_audio": null,
      "question_video": null,
      "map_id": 4588300,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Ans. C) Lymphocytic pleocytosis, low sugar, high protein</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:18px;\">The presentation of fever, headache, altered sensorium, along with basal exudates and meningeal enhancement on CT scan, is suggestive of tubercular meningitis.</span></li><li><span style=\"font-size:18px;\">Classic CSF findings in tuberculous meningitis:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:18px;\">Lymphocytic pleocytosis (predominantly lymphocytes)</span></li><li><span style=\"font-size:18px;\">↓ Low glucose (due to consumption by bacteria and inflammatory cells)</span></li><li><span style=\"font-size:18px;\">↑ High protein (due to increased permeability of the blood-brain barrier)</span></li></ul></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Option A. Lymphocytic pleocytosis, low sugar, low protein</strong>: This CSF profile is more typical of viral (aseptic) meningitis, where the glucose levels might be normal or slightly decreased, and protein levels are usually not as elevated as in bacterial meningitis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Option B. Polymorphonuclear pleocytosis, normal sugar, high protein</strong>: Polymorphonuclear pleocytosis is initially seen in bacterial meningitis, but the glucose levels are usually decreased, not normal.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Option D. Lymphocytic pleocytosis, normal sugar, high protein</strong>: This CSF profile could be seen in some cases of viral meningitis or partially treated bacterial meningitis, but the low sugar is a more distinguishing feature of untreated bacterial meningitis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:18px;\">In bacterial meningitis, the CSF analysis often shows lymphocytic pleocytosis, low glucose levels due to bacterial consumption, and high protein levels as a result of the inflammatory response.</span></p></li><li><span style=\"font-size:18px;\">This helps distinguish bacterial meningitis from other types of meningitis such as viral, where glucose levels might be normal or slightly decreased, and protein levels are usually not as elevated.</span></li><li><span style=\"font-size:18px;\">Always think of Tubercular meningitis when:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:18px;\">Subacute onset</span></li><li><span style=\"font-size:18px;\">Altered sensorium</span></li><li><span style=\"font-size:18px;\">Basal meningeal enhancement on imaging</span></li><li><span style=\"font-size:18px;\">CSF: lymphocytes + low glucose + high protein</span></li></ul></li></ul>",
      "correct_choice_id": 164018,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41081,
      "choices": [
        {
          "id": 164020,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Depresses an already compromised myocardium </span></span></span></span></p>"
        },
        {
          "id": 164021,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Permits the use of limited FiO<sub>2</sub> only </span></span></span></span></p>"
        },
        {
          "id": 164022,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Is less soluble than nitrogen </span></span></span></span></p>"
        },
        {
          "id": 164023,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Causes the expansion of air filled body cavities</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitrous oxide is contraindicated in patients with pneumothorax, pneumopericardium or intestinal obstruction, because it:</span></span></span></span></p>",
      "unique_key": "Q5373317",
      "question_audio": null,
      "question_video": null,
      "map_id": 4588321,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Causes the expansion of air filled body cavities</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitrous oxide is contraindicated in conditions like pneumothorax, pneumopericardium, or intestinal obstruction because it is approximately 34 times more soluble than nitrogen in blood. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This higher solubility leads to nitrous oxide diffusing into air-filled spaces faster than nitrogen can diffuse out, causing an expansion of these cavities. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In conditions like pneumothorax or intestinal obstruction, the expansion of these air-filled cavities can worsen the patient&#39;s clinical condition or lead to further complications.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Depresses an already compromised myocardium</strong>: Nitrous oxide does have some mild myocardial depressant effects, but this is not the primary reason for its contraindication in the conditions mentioned.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Permits the use of limited FiO<sub>2</sub> only</strong>: While nitrous oxide does limit the fraction of inspired oxygen (FIO2) due to its own volume in the gas mixture, this is not the primary reason for its contraindication in cases involving air-filled body cavities.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Is less soluble than nitrogen</strong>: This statement is incorrect; nitrous oxide is more soluble than nitrogen, which is precisely why it rapidly fills air cavities and is thus contraindicated.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitrous oxide should be avoided in situations where air-filled cavities are present within the body, such as pneumothorax, pneumopericardium, or intestinal obstruction, due to its property of rapidly expanding these spaces. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This expansion occurs because nitrous oxide diffuses into the cavities faster than nitrogen can escape, potentially leading to worsening of the condition or complications.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164023,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41084,
      "choices": [
        {
          "id": 164032,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2 &amp; 4</span></span></span></span></p>"
        },
        {
          "id": 164033,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2 Only</span></span></span></span></p>"
        },
        {
          "id": 164034,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3 &amp; 4</span></span></span></span></p>"
        },
        {
          "id": 164035,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4 Only</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An internal medicine doctor is discussing vaccine recommendations for elderly patients during a community health workshop. Given the specific vulnerabilities and health risks associated with older adults, which vaccines are recommended for this age group?</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rotavirus vaccine</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Meningococcal vaccine</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diphtheria toxoid</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Varicella Zoster vaccine</span></span></span></span></li>\r\n</ol>",
      "unique_key": "Q5824590",
      "question_audio": null,
      "question_video": null,
      "map_id": 4588364,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A) 2 &amp; 4</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Meningococcal vaccine is recommended for the elderly, particularly those at risk due to potential immunocompromising conditions, travel to countries where meningococcal disease is common, or those who might have specific health conditions that increase their risk of meningococcal disease. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Varicella Zoster vaccine is widely recommended for the elderly to prevent shingles, a disease caused by the reactivation of the chickenpox virus, which can be particularly severe in older adults.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option 1. Rotavirus vaccine:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This vaccine is generally recommended for infants and young children to protect against rotavirus, which causes severe diarrhea. It is not typically given to the elderly.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option 3. Diphtheria toxoid:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While periodic booster shots (often combined as Tdap &mdash; tetanus, diphtheria, and pertussis) are recommended for all adults every 10 years, this vaccine itself is not specifically emphasized for the elderly over others and does not have the particular relevance that shingles and meningococcal vaccines do in this age group.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDC GUIDELINES FOR IMMUNIZATION OF OLDER PEOPLE</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Influenza intramuscular inactivated vaccine</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumococcal vaccine once</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tetanus-diphtheria toxoid (Td) booster every 10 years</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In selected patients aged 60 years or more: Herpes zoster (shingles), Hepatitis A, Hepatitis B, Meningococcal disease, Varicella, MMR, Yellow fever vaccine (for travellers)</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164032,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41086,
      "choices": [
        {
          "id": 164040,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">Fibrin clot</span></p>"
        },
        {
          "id": 164041,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">Encapsulating Peritoneal sclerosis</span></p>"
        },
        {
          "id": 164042,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">CAPD Peritonitis</span></p>"
        },
        {
          "id": 164043,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">Tunnel infection</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">A 50-year-old male is undergoing continuous ambulatory peritoneal dialysis (CAPD) since 4 months presents with pain abdomen and cloudy effluent since 1 day. The CAPD fluid total WBC count is 175 cells/mm<sup>3</sup> with 80% neutrophils. The likely diagnosis is:</span></p>",
      "unique_key": "Q6123717",
      "question_audio": null,
      "question_video": null,
      "map_id": 4588666,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Ans. C) CAPD Peritonitis</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">CAPD peritonitis is a common complication of peritoneal dialysis and is characterized by signs of infection such as cloudy dialysis fluid, abdominal pain, and an increase in dialysis fluid WBC, primarily neutrophils.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">The diagnosis is typically made when dialysis effluent WBC count is greater than 100 cells/mm³, with at least 50% neutrophils.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Option A. Fibrin clot</strong>: While fibrin clots can occasionally form in the dialysis fluid, they do not cause an increase in WBC count or symptoms of infection.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Option B. Encapsulating Peritoneal sclerosis</strong>: This is a rare but serious complication of long-term peritoneal dialysis that typically presents with intestinal obstruction symptoms and would not typically cause cloudy effluent or an acute increase in WBC count in the dialysis fluid.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Option D. Tunnel infection</strong>: This refers to an infection along the tract where the catheter enters the body. While it may cause local signs of infection, it does not directly affect the dialysis fluid WBC count unless there is an associated peritonitis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">In patients on CAPD who present with cloudy effluent and abdominal pain, along with an elevated WBC count in the dialysis fluid, particularly with a high percentage of neutrophils, the diagnosis of CAPD-associated peritonitis should be considered.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">Prompt recognition and treatment of this condition are critical to patient outcomes.</span></p></li></ul>",
      "correct_choice_id": 164042,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41088,
      "choices": [
        {
          "id": 164048,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pituitary adenoma </span></span></span></span></p>"
        },
        {
          "id": 164049,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TSH-secreting pituitary tumor </span></span></span></span></p>"
        },
        {
          "id": 164050,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroid target receptor insensitivity </span></span></span></span></p>"
        },
        {
          "id": 164051,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary hypothyroidism</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old girl, who was evaluated for short height was found to have an enlarged pituitary gland. Her T4 was low and TSH was increased. Which of the following is the most likely diagnosis?</span></span></span></span></p>",
      "unique_key": "Q5588701",
      "question_audio": null,
      "question_video": null,
      "map_id": 4588688,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Primary hypothyroidism</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presentation of a young individual with short stature, an enlarged pituitary gland, low T4 (thyroxine), and elevated TSH (thyroid-stimulating hormone) suggests primary hypothyroidism. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In primary hypothyroidism, the thyroid gland is underactive or not producing enough thyroid hormones (like T4), leading to an elevation in TSH levels as the pituitary gland tries to stimulate the thyroid to produce more hormones. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The enlarged pituitary gland could be due to hyperplasia as it overworks to produce more TSH in an attempt to compensate for the low thyroid hormone levels.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pituitary adenoma</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While a pituitary adenoma could cause enlargement of the pituitary gland, it would not typically result in the hormonal profile described (low T4 with high TSH), unless it is a TSH-secreting adenoma, which is quite rare. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. TSH-secreting pituitary tumor</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a rare type of pituitary adenoma that secretes TSH and would typically lead to high levels of both TSH and thyroid hormones (a condition known as secondary hyperthyroidism), which does not match the described scenario. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Thyroid target receptor insensitivity</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This condition, also known as <strong>thyroid</strong> <strong>hormone resistance</strong>, would lead to elevated levels of both thyroid hormones and TSH due to a lack of feedback inhibition. This does not match the low T4 level described in the scenario.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary hypothyroidism is characterized by low levels of thyroid hormones and elevated TSH levels due to the pituitary gland&#39;s attempt to stimulate the underactive thyroid. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An enlarged pituitary gland in this context could be a result of hyperplasia from the increased production of TSH.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164051,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41089,
      "choices": [
        {
          "id": 164052,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zilucoplan is used for the treatment of Rheumatoid Arthritis, acting as a TNF-alpha inhibitor to reduce inflammation and slow disease progression. </span></span></span></span></p>"
        },
        {
          "id": 164053,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zilucoplan is approved for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), where it acts as a C5 complement inhibitor, preventing hemolysis. </span></span></span></span></p>"
        },
        {
          "id": 164054,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zilucoplan is indicated for the management of Myasthenia Gravis, functioning as a complement inhibitor that targets the C5 component, reducing the severity of muscle weakness. </span></span></span></span></p>"
        },
        {
          "id": 164055,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zilucoplan is utilized in treating Chronic Lymphocytic Leukemia, serving as a BTK inhibitor to block cancer cell growth and survival.</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following best describes the indication and mechanism of action of the newly approved drug Zilucoplan?</span></span></span></span></p>",
      "unique_key": "Q6570897",
      "question_audio": null,
      "question_video": null,
      "map_id": 4588759,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C) Zilucoplan is indicated for the management of Myasthenia Gravis, functioning as a complement inhibitor that targets the C5 component, reducing the severity of muscle weakness.</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zilucoplan&#39;s mechanism of action involves the inhibition of the C5 component of the complement cascade, which can lead to decreased formation of the membrane attack complex (MAC). </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is particularly beneficial in diseases like myasthenia gravis, where the destruction of the neuromuscular junction by the immune system results in muscle weakness. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">By inhibiting complement activity, zilucoplan reduces the immune-mediated damage at the neuromuscular junction, thus alleviating symptoms of the disease.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Zilucoplan is used for the treatment of Rheumatoid Arthritis, acting as a TNF-alpha inhibitor to reduce inflammation and slow disease progression</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect, as zilucoplan is not a TNF-alpha inhibitor but a complement inhibitor, and it is not used for rheumatoid arthritis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Zilucoplan is approved for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), where it acts as a C5 complement inhibitor, preventing hemolysis</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While this description of the mechanism is partially correct in terms of the drug&#39;s action, zilucoplan is not approved for PNH but rather for myasthenia gravis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Zilucoplan is utilized in treating Chronic Lymphocytic Leukemia, serving as a BTK inhibitor to block cancer cell growth and survival</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect, zilucoplan does not act as a BTK inhibitor; it targets the complement system and is not used in the treatment of leukemia.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zilucoplan&#39;s approval for myasthenia gravis highlights the expanding role of complement inhibitors in treating autoimmune conditions. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">By targeting the C5 component, zilucoplan effectively reduces the exacerbation of muscle weakness, offering a novel therapeutic approach for patients with this challenging autoimmune disorder.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164054,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41090,
      "choices": [
        {
          "id": 164056,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Slight agreement </span></span></span></span></p>"
        },
        {
          "id": 164057,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fair agreement </span></span></span></span></p>"
        },
        {
          "id": 164058,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Moderate agreement </span></span></span></span></p>"
        },
        {
          "id": 164059,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Substantial agreement</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A research team is analyzing the consistency of diagnostic assessments performed by two different clinicians on two separate occasions for the same set of patients. To evaluate the reliability of the diagnoses across these two occasions, they decide to use a statistical method that measures the extent of agreement between the two sets of assessments, correcting for chance agreement. Based on the following information about Kappa coefficient (K), which interpretation best applies if they calculate a Kappa value of 0.45?</span></span></span></span></p>",
      "unique_key": "Q2133484",
      "question_audio": null,
      "question_video": null,
      "map_id": 4589080,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C) Moderate agreement</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Kappa coefficient (K) is a statistic used to measure the reliability of agreement between two sets of categorical data. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It corrects for the amount of agreement that could be expected by chance alone. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A Kappa value of 0.45 falls within the range of 0.41 to 0.60, which is interpreted as moderate agreement according to the scale provided. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This indicates that there is a moderate consistency in the diagnostic assessments made by the two clinicians beyond what would be expected just by chance.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Slight agreement:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This category is defined by a Kappa value ranging from 0 to 0.20. A Kappa of 0.45 exceeds this range.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Fair agreement:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Defined by a Kappa value from 0.21 to 0.40. The value of 0.45 is just above this range.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Substantial agreement:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This would require a Kappa value between 0.61 and 0.80, which is higher than 0.45.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">KAPPA COEFFICIENT (K)</span></span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"list-style-type:none\">&nbsp;</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indicates the extent of agreement between frequencies of two sets of data collected on two different occasions</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Formula</span></span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: K = O-E/(1 &ndash; E)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interpretation:</span></span></strong></span></span>\r\n\t<ul>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">0 = agreement equivalent to chance.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">0 &ndash; 0.20 = slight agreement.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">0.21 &ndash; 0.40 = fair agreement.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">0.41 &ndash; 0.60 = moderate agreement.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">0.61 &ndash; 0.80 = substantial agreement.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">0.81 &ndash; 0.99 = near perfect agreement</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1 = perfect agreement.</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>",
      "correct_choice_id": 164058,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41091,
      "choices": [
        {
          "id": 164060,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenocarcinoma of the esophagus </span></span></span></span></p>"
        },
        {
          "id": 164061,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gastric adenocarcinoma </span></span></span></span></p>"
        },
        {
          "id": 164062,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Krukenberg tumor </span></span></span></span></p>"
        },
        {
          "id": 164063,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-small cell adenocarcinoma of the lung</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old white man presents to the emergency department complaining of burning retrosternal chest pain after meals. The pain is relieved by antacids. The patient&rsquo;s ECG is normal, and x-ray of the chest is remarkable for an 8-cm hiatal hernia. This patient is at risk for developing which of the following types of cancer?</span></span></span></span></p>",
      "unique_key": "Q2792746",
      "question_audio": null,
      "question_video": null,
      "map_id": 4606211,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Adenocarcinoma of the esophagus</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenocarcinoma of the esophagus is strongly associated with Barrett&#39;s esophagus and chronic GERD. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The acid reflux associated with a hiatal hernia increases the risk of developing this type of cancer.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Gastric adenocarcinoma</strong>: While there is a link between gastric reflux and gastric cancer, the patient&#39;s hiatal hernia and symptoms are more specifically associated with an increased risk of esophageal adenocarcinoma.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Krukenberg tumor</strong>: This is a metastatic gastric cancer that typically involves the ovaries, not directly related to GERD or hiatal hernia.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Non-small cell adenocarcinoma of the lung</strong>: This type of lung cancer is not related to GERD or hiatal hernias. Risk factors include smoking and exposure to certain environmental factors.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with chronic GERD and a large hiatal hernia is at increased risk for Barrett&#39;s esophagus, which can progress to adenocarcinoma of the esophagus. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, these patients should be monitored for potential progression to dysplasia and adenocarcinoma.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164060,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41092,
      "choices": [
        {
          "id": 164064,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">22q translocation </span></span></span></span></p>"
        },
        {
          "id": 164065,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">11q deletion </span></span></span></span></p>"
        },
        {
          "id": 164066,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">7p translocation </span></span></span></span></p>"
        },
        {
          "id": 164067,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">n-myc amplification</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 11-year-old girl presents with a tibial mass. Histopathological examination reveals a small round cell tumor. Which of the following molecular findings is most likely to be present?</span></span></span></span></p>",
      "unique_key": "Q2908148",
      "question_audio": null,
      "question_video": null,
      "map_id": 4606362,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A) 22q translocation</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The description of a small round cell tumor in a child, especially involving a long bone like the tibia, is highly suggestive of Ewing&#39;s sarcoma. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A characteristic molecular finding in Ewing&#39;s sarcoma is a translocation involving chromosome 22, specifically t(11;22)(q24;q12). </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This translocation leads to the fusion of the EWSR1 gene on chromosome 22 to the FLI1 gene on chromosome 11, creating a fusion protein that plays a role in the pathogenesis of the tumor.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. 11q deletion</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This genetic aberration is not typically associated with small round cell tumors of bone. Deletions on chromosome 11q are more commonly seen in neuroblastomas and some hematologic malignancies.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 7p translocation</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Translocations involving chromosome 7p are not characteristically found in small round cell tumors of bone. They may occur in other types of cancers but are not indicative of Ewing&#39;s sarcoma.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. n-myc amplification</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Amplification of the n-myc gene is a hallmark of neuroblastoma, another type of cancer that can present as a small round cell tumor, particularly in children. However, it is not commonly associated with tumors of the bone like Ewing&#39;s sarcoma.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of a small round cell tumor in a child&#39;s tibia, along with the characteristic translocation involving chromosome 22 (t(11;22)(q24;q12)), suggests a diagnosis of Ewing&#39;s sarcoma. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This translocation results in a fusion gene that contributes to tumor formation.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164064,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41093,
      "choices": [
        {
          "id": 164068,
          "text": "<p>​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resmetirom is utilized for the treatment of Type 2 Diabetes Mellitus, functioning as an insulin sensitizer by activating PPAR-gamma receptors to improve glucose utilization. </span></span></span></span></p>"
        },
        {
          "id": 164069,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resmetirom is used in the management of atrial fibrillation, where it acts as a potassium channel blocker to slow down heart rate and improve heart rhythm. </span></span></span></span></p>"
        },
        {
          "id": 164070,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resmetirom is indicated for the treatment of non-alcoholic steatohepatitis (NASH), acting as a selective thyroid hormone receptor beta (THR-&beta;) agonist to reduce liver fat and fibrosis. </span></span></span></span></p>"
        },
        {
          "id": 164071,
          "text": "<p>​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resmetirom is prescribed for the lowering of high cholesterol, operating as an HMG-CoA reductase inhibitor to reduce the production of cholesterol in the liver. </span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which statement accurately describes the therapeutic application and mechanism of action of Resmetirom?</span></span></span></span></p>",
      "unique_key": "Q3644836",
      "question_audio": null,
      "question_video": null,
      "map_id": 4606383,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C) Resmetirom is indicated for the treatment of non-alcoholic steatohepatitis (NASH), acting as a selective thyroid hormone receptor beta (THR-&beta;) agonist to reduce liver fat and fibrosis.</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resmetirom targets the thyroid hormone receptor beta (THR-&beta;) which is predominantly found in the liver. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">By acting on this receptor, resmetirom mimics the action of thyroid hormones that are naturally occurring regulators of metabolism and energy use. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of NASH, resmetirom&#39;s activation of THR-&beta; leads to enhanced lipid metabolism and reduced liver fat, as well as potential improvements in liver fibrosis, addressing key aspects of the pathology of NASH.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Resmetirom is utilized for the treatment of Type 2 Diabetes Mellitus, functioning as an insulin sensitizer by activating PPAR-gamma receptors to improve glucose utilization</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is incorrect. While PPAR-gamma receptors are indeed targeted by some diabetes medications (like thiazolidinediones) to improve insulin sensitivity, resmetirom does not function via this mechanism or treat diabetes.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Resmetirom is used in the management of atrial fibrillation, where it acts as a potassium channel blocker to slow down heart rate and improve heart rhythm</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect. Potassium channel blockers are used to manage heart rate in conditions like atrial fibrillation, but resmetirom does not function as a potassium channel blocker nor is it used for this condition.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Resmetirom is prescribed for the lowering of high cholesterol, operating as an HMG-CoA reductase inhibitor to reduce the production of cholesterol in the liver</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect. While HMG-CoA reductase inhibitors (statins) are commonly used to reduce cholesterol levels, resmetirom does not operate through this pathway. It acts specifically on the thyroid hormone pathway in the liver.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resmetirom&rsquo;s mechanism of action as a selective THR-&beta; agonist highlights its novel approach in treating NASH by reducing liver fat and potentially fibrosis through enhanced metabolism and energy expenditure pathways primarily in the liver, making it a targeted treatment for this specific liver condition.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164070,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41094,
      "choices": [
        {
          "id": 164072,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Construct validity </span></span></span></span></p>"
        },
        {
          "id": 164073,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">External validity </span></span></span></span></p>"
        },
        {
          "id": 164074,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Concurrent validity </span></span></span></span></p>"
        },
        {
          "id": 164075,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Face validity</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A clinical research team is evaluating the efficacy of a new drug for treating chronic pain. They plan to compare the drug&#39;s performance with existing pain management protocols using various measures of effectiveness. To ensure the relevance and applicability of their results, which type of validity should the researchers primarily focus on to guarantee that their findings can be generalized to patients outside the study?</span></span></span></span></p>",
      "unique_key": "Q9900216",
      "question_audio": null,
      "question_video": null,
      "map_id": 4606674,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B) External validity</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">External validity is crucial for determining whether the results of the clinical trial can be generalized to broader and varied populations beyond the specific conditions of the study. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a new drug&#39;s clinical trial, establishing external validity means demonstrating that the positive outcomes observed can be expected to apply to different settings, different types of patients, and over different time periods. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is essential for the broader acceptance and application of the drug in routine clinical practice.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Construct validity:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This validity confirms that the study accurately measures and reflects the theoretical constructs it aims to test, such as the theoretical underpinnings of pain management in this scenario. It&rsquo;s important but does not address generalization.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Concurrent validity:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This type of validity refers to the correlation of the new drug&#39;s effects with those of existing treatments measured at the same time. It&rsquo;s useful for showing that the new drug performs similarly to or better than existing treatments but doesn&#39;t address broader generalization.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Face validity:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This simplest form of validity assesses whether the test appears effective in a superficial sense and doesn&#39;t necessarily provide evidence about the appropriateness or effectiveness of the drug across different populations.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">External validity</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Assuming causal relationship between 2 variables, defines if our theory can be generalized to the broader population.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164073,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41095,
      "choices": [
        {
          "id": 164076,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Goodpasture syndrome </span></span></span></span></p>"
        },
        {
          "id": 164077,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wegener&#39;s granulomatosis </span></span></span></span></p>"
        },
        {
          "id": 164078,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Microscopic polyangiitis </span></span></span></span></p>"
        },
        {
          "id": 164079,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polyarteritis nodosa</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A young female presents with rhinitis, not subsiding with antihistaminics, along with recurrent hemoptysis &amp; glomerulonephritis. Which of the following is NOT an important differential diagnosis to be considered in the given scenario?</span></span></span></span></p>",
      "unique_key": "Q7111584",
      "question_audio": null,
      "question_video": null,
      "map_id": 4606695,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Polyarteritis nodosa</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polyarteritis nodosa (PAN) is a vasculitis that typically does not involve the lungs and hence would not be associated with hemoptysis, which is one of the presenting symptoms in this case. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PAN is more associated with systemic symptoms, renal involvement, and may involve the mesenteric and hepatic arteries but not the pulmonary circulation.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Goodpasture syndrome</strong>: This involves the lungs and kidneys and can present with hemoptysis and glomerulonephritis, making it a potential diagnosis in this scenario.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Wegener&#39;s granulomatosis (GPA)</strong>: Now known as Granulomatosis with polyangiitis, it is a type of vasculitis that often presents with sinusitis (which may present like persistent rhinitis), along with renal and pulmonary involvement, including hemoptysis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Microscopic polyangiitis</strong>: This also involves small vessels and can present with symptoms affecting the kidneys and lungs, including hemoptysis and glomerulonephritis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of a young female presenting with rhinitis, hemoptysis, and glomerulonephritis, the most likely differential diagnoses include Vasculitis that affect both the respiratory and renal systems, such as Goodpasture syndrome, Granulomatosis with polyangiitis, and Microscopic polyangiitis. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polyarteritis nodosa typically does not involve the pulmonary system and would not account for hemoptysis, making it less likely in this clinical scenario.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164079,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41097,
      "choices": [
        {
          "id": 164084,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostaglandin analogues </span></span></span></span></p>"
        },
        {
          "id": 164085,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">H2-receptor antagonists </span></span></span></span></p>"
        },
        {
          "id": 164086,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proton pump inhibitors </span></span></span></span></p>"
        },
        {
          "id": 164087,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antacids</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which group of drugs is most effective for the healing of Non-Steroidal Anti-inflammatory Drug (NSAID)-induced gastric ulcer:</span></span></span></span></p>",
      "unique_key": "Q5555807",
      "question_audio": null,
      "question_video": null,
      "map_id": 4606817,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">) Proton pump inhibitors</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proton pump inhibitors (PPIs) are the most effective group of drugs for the healing of Non-Steroidal Anti-Inflammatory Drug (NSAID)-induced gastric ulcers. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PPIs work by significantly reducing stomach acid production, thus allowing gastric ulcers more time to heal and reducing the risk of further irritation or bleeding. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PPIs are more effective than H2-receptor antagonists in inhibiting gastric acid secretion, making them the preferred choice for treating and preventing NSAID-induced ulcers.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Prostaglandin analogues:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While these can help protect the gastric mucosa by enhancing mucus and bicarbonate production and promoting blood flow, they are generally considered less effective than PPIs for healing existing ulcers.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. H2-receptor antagonists:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These reduce acid production by blocking H2 receptors in stomach lining cells. They are effective for many peptic ulcers but are less potent compared to PPIs in acid suppression.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Antacids:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These neutralize stomach acid and provide symptomatic relief but do not promote ulcer healing as effectively as PPIs, nor do they prevent the recurrence of ulcers.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proton pump inhibitors are the most effective treatment for NSAID-induced gastric ulcers due to their potent acid suppression capabilities. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This allows for faster healing of the gastric mucosa and reduces complications associated with these ulcers.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164086,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41099,
      "choices": [
        {
          "id": 164092,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">30% of the calories from protein are used for its metabolic processing, reducing the net caloric gain. </span></span></span></span></p>"
        },
        {
          "id": 164093,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only 70% of the calories from protein are absorbed by the body, the rest being lost as heat. </span></span></span></span></p>"
        },
        {
          "id": 164094,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">30% of the calories from protein are converted directly into body fat. </span></span></span></span></p>"
        },
        {
          "id": 164095,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">70% of the calories from protein are expended in the digestion process alone.</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a workshop on nutrition and energy metabolism for fitness trainers, a dietitian discusses how the body&#39;s energy expenditure is affected by the type of food consumed. She explains the concept of the thermic effect of food (TEF), which varies significantly among different macronutrients due to their specific dynamic actions (SDA). What does the 30% thermic effect observed for proteins imply regarding the energy usage from a meal consisting primarily of proteins?</span></span></span></span></p>",
      "unique_key": "Q4917143",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607009,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A) 30% of the calories from protein are used for its metabolic processing, reducing the net caloric gain.</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The thermic effect of food (TEF) is an important component of total daily energy expenditure and refers to the amount of energy that is required to process food&mdash;digesting, absorbing, and storing nutrients. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For proteins, a thermic effect of 30% means that 30% of the energy consumed from proteins is used just for processing those proteins. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is due to proteins requiring more energy to break down compared to carbohydrates and fats. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, if 100 calories of protein are consumed, 30 of those calories will be used up in the metabolic processes involved, effectively providing the body with 70 usable calories.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Only 70% of the calories from protein are absorbed by the body, the rest being lost as heat.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This option simplifies the concept incorrectly by implying that the unutilized calories are only lost as heat, rather than being utilized for metabolic processes.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 30% of the calories from protein are converted directly into body fat.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is incorrect as the 30% represents energy used for metabolic processing, not conversion into fat.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 70% of the calories from protein are expended in the digestion process alone.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This reverses the actual distribution and role of TEF, misrepresenting how energy is used in metabolism.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"list-style-type:none\">&nbsp;</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Specific dynamic action (SDA) [Thermic effect of food (TEF)/Dietary induced thermogenesis (DIT)]</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TEF is the amount of energy expenditure above the basal metabolic rate due to the cost of processing food for use and storage.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TEF is the energy required for digestion, absorption, and disposal of ingested nutrients</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TEF magnitude depends on the composition of food consumed: Proteins (20-30% of energy consumed &gt; Carbohydrates (5-15%) &gt; Fats (at most 5-15%)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A thermic effect of 30% for proteins means that 100 calories of protein only end up as 70 usable calories.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164092,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41101,
      "choices": [
        {
          "id": 164100,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Catastrophic anti-phospholipid antibody syndrome </span></span></span></span></p>"
        },
        {
          "id": 164101,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary anti-phospholipid antibody syndrome </span></span></span></span></p>"
        },
        {
          "id": 164102,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombotic Thrombocytopenic Purpura (TTP)</span></span></span></span></p>"
        },
        {
          "id": 164103,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protein C deficiency</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 26-year-old female is suffering from recurrent abortions and thrombosis of deep veins, thrombocytopenia, and a recent MI. The most likely diagnosis is:</span></span></span></span></p>",
      "unique_key": "Q6245849",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607131,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Primary antiphospholipid antibody syndrome</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of arterial and venous thromboses, recurrent fetal loss, and thrombocytopenia in a young woman suggests APS, which is characterized by the persistent presence of antiphospholipid antibodies (such as lupus anticoagulant, anticardiolipin antibodies, and anti-&beta;2 glycoprotein I antibodies). </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The diagnosis is confirmed with serological tests showing these antibodies.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Catastrophic antiphospholipid antibody syndrome</strong>: This is a severe form of APS that can be life-threatening and often leads to multiple organ failures. The &quot;catastrophic&quot; variant is less common, and it is typically reserved for acute presentations involving multiple organ systems over a short period.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Thrombotic Thrombocytopenic Purpura (TTP)</strong>: TTP is a hematologic disorder that can cause thrombocytopenia and microangiopathic hemolytic anemia, but it does not typically present with recurrent fetal loss or deep vein thrombosis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Protein C Deficiency</strong>: This hereditary or acquired condition increases the risk of thrombosis, but it is not commonly associated with recurrent miscarriages or a broader spectrum of clinical findings as seen in antiphospholipid antibody syndrome.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with a history of recurrent miscarriages and thrombotic events, along with laboratory findings of thrombocytopenia, antiphospholipid antibody syndrome should be considered as a differential diagnosis, and appropriate serological tests should be conducted to confirm the presence of antiphospholipid antibodies.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41102,
      "choices": [
        {
          "id": 164104,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LMW heparin directly inhibits thrombin whereas unfractionated heparin acts via activation of antithrombin </span></span></span></span></p>"
        },
        {
          "id": 164105,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LMW heparins have lesser risk of causing bleeding </span></span></span></span></p>"
        },
        {
          "id": 164106,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LMW heparin can be given subcutaneously as well as orally </span></span></span></span></p>"
        },
        {
          "id": 164107,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LMW heparin has consistent bioavailability</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low Molecular Weight (LMW) heparin is preferred over unfractionated heparin because:&nbsp;</span></span></span></span></p>",
      "unique_key": "Q2101234",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607152,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D)</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>LMW heparin has consistent bioavailability</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LMW heparin has a more consistent bioavailability compared to unfractionated heparin. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This consistency results from its smaller and more uniform molecule size, which allows it to be absorbed more predictably when administered subcutaneously. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This leads to a more predictable anticoagulant effect, reducing the need for routine monitoring of the aPTT (activated partial thromboplastin time) levels, which is often necessary with unfractionated heparin.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>LMW heparin directly inhibits thrombin whereas unfractionated heparin acts via activation of antithrombin</strong>: This is incorrect. Both LMW heparin and unfractionated heparin potentiate the action of antithrombin III. However, unfractionated heparin is more effective at inactivating thrombin due to its larger size, which can bridge antithrombin and thrombin. LMW heparin is more effective at inhibiting factor Xa.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>LMW heparins have lesser risk of causing bleeding</strong>: While LMW heparin does generally have a lower risk of major bleeding compared to unfractionated heparin, particularly in the context of procedures and surgery, it is not the primary reason it is preferred. It is still associated with significant bleeding risk.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>LMW heparin can be given subcutaneously as well as orally</strong>: This is incorrect. LMW heparin can be given subcutaneously but not orally. Heparins are not absorbed orally due to their large polysaccharide structures.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LMW heparin is preferred over unfractionated heparin mainly due to its more predictable pharmacokinetics, which result from its higher bioavailability and longer half-life, allowing for easier dosing without the need for frequent monitoring of aPTT. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This makes it especially useful for outpatient anticoagulation therapy.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164107,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41105,
      "choices": [
        {
          "id": 164116,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A and R are true statements and R is the correct explanation of A</span></span></span></span></p>"
        },
        {
          "id": 164117,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A and R are true statements but R is not the correct explanation of A</span></span></span></span></p>"
        },
        {
          "id": 164118,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A is true but R is false</span></span></span></span></p>"
        },
        {
          "id": 164119,
          "text": "<p>​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Both A and R are false</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Consider the following statements regarding the use of malathion during epidemics:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Assertion (A): Malathion is used as an Ultra-Low Volume (ULV) during epidemics.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reasoning (R): ULV fogging has a residual effect.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Evaluate the correctness of these statements and the relationship between them.&nbsp;</span></span></span></span></p>",
      "unique_key": "Q4066894",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607325,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C) A is true but R is false</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Assertion (A):</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> True. Malathion is indeed used as an Ultra-Low Volume (ULV) spray during epidemics for vector control, particularly for controlling mosquito populations that may transmit diseases such as malaria or West Nile virus. ULV applications involve spraying very fine aerosol droplets that contain small amounts of insecticide to kill mosquitoes and other pests.</span></span></span></span><br />\r\n\t&nbsp;</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reasoning (R):</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> False. ULV fogging, while effective for the immediate knockdown of mosquito populations, does not have a significant residual effect. The primary advantage of ULV fogging is its ability to cover large areas quickly and with relatively small amounts of pesticide. However, it does not leave behind a lasting residue like some other forms of pesticide application, which would continue to kill or repel pests over a longer period.</span></span></span></span><br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"list-style-type:none\">&nbsp;</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malathion is used as ULV during epidemics using aircraft (esp for Aircraft) in dosage 98% pure malathion 1-2 ounces/acre.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ULV has no diluent (hence its more effective than Thermal fogging).</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ULV has No residual effect (So multiple applications are required).</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164118,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41107,
      "choices": [
        {
          "id": 164124,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune complex </span></span></span></span></p>"
        },
        {
          "id": 164125,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glomerular crescents </span></span></span></span></p>"
        },
        {
          "id": 164126,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patchy tubular necrosis </span></span></span></span></p>"
        },
        {
          "id": 164127,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mesangial deposits</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old patient develops cardiogenic shock following acute myocardial infarction. His urine output decreases in the next few days. He has increased serum urea and creatinine; urine analysis reveals no glucose or protein but numerous hyaline casts are present. After a few days, he develops polyuria and serum creatinine levels fall. Histopathology of renal biopsy in this patient would reveal:</span></span></span></span></p>",
      "unique_key": "Q2626886",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607547,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Patchy tubular necrosis</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of decreased urine output following cardiogenic shock, the presence of increased serum urea and creatinine with hyaline casts and an absence of protein or glucose in the urine is consistent with ATN. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The polyuria and the falling serum creatinine levels suggest the recovery phase of ATN, where tubular function begins to return, leading to increased urine output and a decrease in serum creatinine. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Histopathology would reveal patchy necrosis of the renal tubules.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Immune complex</strong>: These are typically seen in immunologically mediated diseases like post-infectious glomerulonephritis or lupus nephritis. The clinical context provided does not suggest an immune complex-mediated process.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Glomerular crescents</strong>: These are formed due to proliferation of parietal cells and migration of monocytes and macrophages into Bowman&#39;s space and are indicative of a rapidly progressive glomerulonephritis. This does not align with the patient&#39;s presentation of cardiogenic shock and subsequent renal failure.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Mesangial deposits</strong>: These can be found in several glomerular diseases, such as IgA nephropathy. Mesangial deposits would not explain the acute kidney injury following a reduction in cardiac output.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute tubular necrosis is characterized by an initial phase of renal insufficiency following a significant insult (like cardiogenic shock), with subsequent recovery phase demonstrated by polyuria and decreasing creatinine levels. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal biopsy would typically show patchy necrosis of the tubular epithelial cells.</span></span></li>\r\n</ul>",
      "correct_choice_id": 164126,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41109,
      "choices": [
        {
          "id": 164132,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Promethazine </span></span></span></span></p>"
        },
        {
          "id": 164133,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chlorpheniramine </span></span></span></span></p>"
        },
        {
          "id": 164134,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triprolidine </span></span></span></span></p>"
        },
        {
          "id": 164135,
          "text": "<p>​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loratadine</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following anti-histaminic has very less cholinergic side effects?</span></span></span></span></p>",
      "unique_key": "Q1572547",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607619,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">) Loratadine</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loratadine is a second-generation antihistamine known for having significantly fewer cholinergic side effects, such as dry mouth, urinary retention, and blurred vision, compared to first-generation antihistamines. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This reduced side effect profile is due to loratadine&#39;s decreased ability to cross the blood-brain barrier, which minimizes its effects on the central nervous system and reduces its anticholinergic effects.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Promethazine:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a first-generation antihistamine with notable sedative and anticholinergic effects, often causing more pronounced side effects.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Chlorpheniramine:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Also a first-generation antihistamine, it has greater anticholinergic effects compared to second-generation antihistamines.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Triprolidine:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Another first-generation antihistamine, known for its sedative and anticholinergic properties similar to promethazine and chlorpheniramine.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Second-generation antihistamines like loratadine are preferred for patients who want relief from allergic symptoms without the burdensome anticholinergic and sedative side effects often seen with first-generation antihistamines. </span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164135,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41112,
      "choices": [
        {
          "id": 164144,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Collect carefully and recycle</span></span></span></span></p>"
        },
        {
          "id": 164145,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Controlled combustion</span></span></span></span></p>"
        },
        {
          "id": 164146,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment with chemicals</span></span></span></span></p>"
        },
        {
          "id": 164147,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deep burial</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the recommended method for the safe disposal of mercury?</span></span></span></span></p>",
      "unique_key": "Q6479037",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607622,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A) Collect carefully and recycle</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most environmentally sound method for disposing of mercury is to collect it carefully and recycle it. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mercury is a hazardous material that can cause serious environmental and health issues if not handled properly. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recycling mercury allows it to be reused in a way that prevents release into the environment and reduces the demand for mining new mercury. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This method ensures that mercury is contained and managed in a way that minimizes its environmental impact.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B. Controlled combustion</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This method is not suitable for mercury as it can release toxic mercury vapours into the atmosphere, which are hazardous to both health and the environment.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. Treatment with chemicals</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While chemical stabilization can reduce the mobility of mercury, it does not eliminate the risk of environmental contamination and is generally used as a temporary solution prior to further handling or recycling.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D. Deep burial</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Burying mercury is not recommended because it can lead to contamination of soil and groundwater sources over time.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MERCURY DISPOSAL</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"list-style-type:none\">&nbsp;</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dispose mercury as a hazardous waste</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Never combine it with organic or inorganic waste</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Never dispose it in sink/drain</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dispose off in &lsquo;Recycling units&rsquo;</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41114,
      "choices": [
        {
          "id": 164152,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta thalassemia intermedia</span></span></span></span></p>"
        },
        {
          "id": 164153,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha thalassemia trait</span></span></span></span></p>"
        },
        {
          "id": 164154,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sickle cell disease</span></span></span></span></p>"
        },
        {
          "id": 164155,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HbE disease</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Haemoglobin electrophoresis can detect all except:</span></span></span></span></p>",
      "unique_key": "Q1558657",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607694,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B)</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Alpha thalassemia trait</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Haemoglobin electrophoresis is effective for identifying hemoglobin variants that have different electrical charges, such as HbS in sickle cell disease, HbE disease, and beta thalassemia. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, it is not as effective for detecting alpha thalassemia trait. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha thalassemia often involves the deletion of one or more genes that encode the alpha-globin chain, which does not produce a distinct hemoglobin variant that can be separated by electrophoresis. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In many cases of alpha thalassemia trait, the hemoglobin electrophoresis may appear normal, so genetic testing is preferred for its diagnosis.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Beta thalassemia intermedia</strong>: This condition produces abnormal hemoglobin which can be detected as a shift or absence of beta-globin chains on electrophoresis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Sickle cell disease</strong>: Characterized by the presence of Hb S, which can be detected on electrophoresis as it migrates differently than Hb A.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>HbE disease</strong>: This is caused by a point mutation in the beta-globin gene leading to Hb E, which can be detected on electrophoresis due to its different migration pattern compared to normal hemoglobin.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemoglobin electrophoresis is a tool that can detect various hemoglobin variants based on their charge differences. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can diagnose conditions like sickle cell disease, HbE disease, and beta thalassemia but has limitations in diagnosing alpha thalassemia trait, which often requires genetic testing due to the normal electrophoresis pattern it can produce.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41116,
      "choices": [
        {
          "id": 164160,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Penicillin G </span></span></span></span></p>"
        },
        {
          "id": 164161,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ceftriaxone + metronidazole </span></span></span></span></p>"
        },
        {
          "id": 164162,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Doxycycline </span></span></span></span></p>"
        },
        {
          "id": 164163,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cefotaxime + vancomycin</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 27-year-old patient presents with suspected pneumococcal meningitis. CSF culture is sent for antibiotic sensitivity. Which empirical antibiotic should be given till culture sensitivity result come?</span></span></span></span></p>",
      "unique_key": "Q1894162",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607716,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D)</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Cefotaxime + vancomycin</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Empirical treatment for suspected bacterial meningitis in adults typically includes a combination of antibiotics that can cross the blood-brain barrier effectively and provide coverage for the most likely causative organisms, including pneumococcus. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cefotaxime</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> or <strong>ceftriaxone</strong> are used to cover a broad range of possible bacteria, including most strains of S. pneumoniae. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vancomycin</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is added to cover potential resistance to standard cephalosporins, especially in regions where pneumococcal resistance to ceftriaxone and cefotaxime is known to occur. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This combination ensures broad-spectrum coverage against both sensitive and resistant strains of bacteria.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Penicillin G</strong>: While effective against many strains of S. pneumoniae, resistance has made it less reliable as a sole agent for empirical therapy in bacterial meningitis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Ceftriaxone + metronidazole</strong>: This combination is not typical for meningitis as metronidazole targets anaerobic bacteria, which are less common causes of meningitis. Ceftriaxone alone would not be sufficient for initial empirical coverage due to resistance issues.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Doxycycline</strong>: This is generally not used in the empirical treatment of meningitis, as it does not adequately cover the most common and most serious pathogens involved.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The empirical treatment for suspected pneumococcal meningitis in adults should initially include a third-generation cephalosporin such as cefotaxime or ceftriaxone, combined with vancomycin. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This regimen offers the necessary broad-spectrum coverage to address both sensitive and resistant strains of pneumococcus, providing effective management until pathogen-specific sensitivities are available.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41118,
      "choices": [
        {
          "id": 164168,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More than 80% of calories should come from fat. </span></span></span></span></p>"
        },
        {
          "id": 164169,
          "text": "<p style=\"list-style-type:none\">​​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The fat content should exceed 2000 kcal. </span></span></span></span></p>"
        },
        {
          "id": 164170,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Total carbohydrates should amount to 400 kcal. </span></span></span></span></p>"
        },
        {
          "id": 164171,
          "text": "<p style=\"list-style-type:none\">​​​​​<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Total calorie content should range from 800-1000 kcal.</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A clinical dietitian is preparing a presentation on therapeutic diets for a hospital staff training session. One of the topics includes the calorie specifications of FDA-approved high-fat diets used for metabolic health issues. What is the true characteristic of such an FDA-approved high-fat diet regarding its caloric content?</span></span></span></span></p>",
      "unique_key": "Q2455384",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607838,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. </span></span></strong><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D) Total calorie content should range from 800-1000 kcal.</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This FDA-approved high-fat diet is structured to contain total calories ranging from 800 to 1000 kcal per day, where a significant portion of the caloric intake, specifically between 500-600 kcal, comes from fats. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This configuration ensures that fats contribute more than 50% of the total caloric intake. The diet also includes moderate amounts of proteins (150 kcal) and carbohydrates (250 kcal), making it balanced for specific therapeutic needs while focusing on higher fat intake. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This structure is designed to manage or improve certain health conditions, leveraging the metabolic impact of a higher fat intake.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. More than 80% of calories should come from fat:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is inaccurate for the given diet composition, where fats provide slightly more than 50% of the calories, not 80%.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. The fat content should exceed 2000 kcal:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This exceeds the total caloric intake and is not aligned with the diet&#39;s design, which specifies a much lower total caloric limit.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Total carbohydrates should amount to 400 kcal:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The specified carbohydrate intake for this diet is 250 kcal, not 400 kcal, making this option incorrect.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">COMPOSITION OF A HIGH-FAT MEAL (FDA)</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"list-style-type:none\">&nbsp;</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Total Calories</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 800-1000</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calories from Protein</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 150 kcal</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calories from Carbohydrates</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 250 kcal</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calories from Fat</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 500-600 kcal</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Percent Calories from Fat</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: &gt;50%</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 164171,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41120,
      "choices": [
        {
          "id": 164176,
          "text": "<p>​​​​​<span style=\"font-size:14.0pt;\">Sensitization of red cells with the antibody globulin</span></p>"
        },
        {
          "id": 164177,
          "text": "<p>​​​​​​<span style=\"font-size:14.0pt;\">Anti-human globulin antiserum</span></p>"
        },
        {
          "id": 164178,
          "text": "<p>​​​​​​<span style=\"font-size:14.0pt;\">Incomplete antibody</span></p>"
        },
        {
          "id": 164179,
          "text": "<p>​​​​​​<span style=\"font-size:14.0pt;\">Non-agglutinating antibody</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">Direct Coomb’s test detects the presence of antibodies on the surface of erythrocytes by using:</span></p>",
      "unique_key": "Q5670478",
      "question_audio": null,
      "question_video": null,
      "map_id": 4607880,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Ans. B) Anti-human globulin antiserum</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">The Direct Coomb’s test involves adding anti-human globulin (also known as <strong>Coomb’s reagent</strong>) to a patient's red blood cells.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">The anti-human globulin reagent binds to any human antibodies that are coating the red blood cells. If agglutination (clumping) occurs, it indicates that antibodies are present on the surface of red blood cells, which is a positive test result.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">This test is often used to detect autoimmune hemolytic anemias or hemolytic disease of the newborn.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Option A. Sensitization of red cells with the antibody globulin</strong>: Sensitization of red blood cells with antibodies occurs in vivo in the patient's body, not as part of the Coombs test procedure.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Option C. Incomplete antibody</strong>: Incomplete antibodies, which are typically IgG, can bind to antigens on red blood cells without causing agglutination until the Coombs reagent is added, which then bridges the gap between antibodies, leading to agglutination.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Option D. Non-agglutinating antibody</strong>: Non-agglutinating antibodies are those that do not cause agglutination by themselves. The Coombs reagent is used to detect these non-agglutinating antibodies bound to the red blood cells by causing agglutination when they bridge the gap between the antibodies.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><span style=\"font-size:14.0pt;\">The Direct Coombs test is a laboratory method for detecting antibodies or complement proteins attached to the surface of red blood cells by using anti-human globulin antiserum, which will agglutinate the red blood cells if such antibodies or complement proteins are present.</span></li></ul>",
      "correct_choice_id": 164177,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}